 
 
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR -246 in 
Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid 
Neoplasms  
 
[STUDY_ID_REMOVED]  
 
Amendment 6  
December 30, 2019  


7,7/($3KDVHE6WXG\WR(YDOXDWHWKH6DIHW\DQG(IILFDF\RI$35 LQ
&RPELQDWLRQZLWK$]DFLWLGLQHIRUWKH7UHDWPHQWRI 730XWDQW0\HORLG
1HRSODVPV


6SRQVRU   0RIILWW&DQFHU&HQWHU
 

'UXJ6XSSOLHU    $SUHD7KHUDSHXWLFV$%
  .DUROLQVND,QVWLWXWH6FLHQFH3DUN
  1REHOVYlJ
   6(6ROQD  6 Z H G H Q 
3ULQFLSDO,QYHVWLJDWRU    'DYLG6DOOPDQ0' 
  0RIILWW&DQFHU&HQWHU 
  0DJQROLD'ULYH  7DPSD)/ 
7HOHSKRQH
  HPDLODGGUHVV GDYLGVDOOPDQ#PRIILWWRUJ 

&R,QYHVWLJDWRUV 5DPL.RPURNML0' 
  (ULF3DGURQ0'
-HI IUH\(/DQFHW0'
   .HQGUD6ZHHW0'   /LQJ=KDQJ0'   .DWK\0F*UDZ3K'3DUWLFLSDWLQJ6LWHV    -RKQV+RSNLQV
   'DQD)DUEHU&DQFHU,QVWLWXWH   &OHYHODQG&OLQLF:HL OO&RUQHOO
6WDWLVWLFLDQ   -RKQ%DUQDUG3K'
$PHQGPHQW   

'DWH  


7DEOHRI&RQWHQWV
 2%-(&7,9(6 
 %$&.*5281'   
 678'<(1'32,176   
 3$7,(176(/(&7,21   
 678'<'(6,*1   
 75($70(173/$1   
 '85$7,212)7+(5$3<   
 '85$7,212))2//2:83   
 &5,7(5,$)255(029$/)520678'<   
 '26,1*'(/$<602',),&$7,216   
 $'9(56((9(1765(325 7,1*5(48,5(0(176   
 3+$50$&(87,&$/,1)250$7,21   
 678'<&$/(1'$5   
 0($685(0(172 )())(&7   
 67$7,67,&$/&216,'(5$7,216   
 /$%25$725<&255(/$7(6   
 5(*8/$725<&216,'(5$7,216   
 5()(5(1&(6   
 $33(1',;$(&2*36   
 $33(1',;%,:*5([ZIP_CODE](&5,7(5,$   
 $33(1',;&:+2&/$66,),&$7,21)25&00/$1'0'6  



3URWRFRO6\QRSVLV

7LWOH$3KDVHE6WXG\WR(YDOXDWHWKH6DIHW\DQG(IILFDF\RI$35 LQ&RPELQDWLRQZLWK
$]DFLWLGLQHIRUWKH7UHDWPHQWRI 730XWDQW0\HORLG1HRSODVPV

6WXG\
2EMHFWLYHV3ULPDU\2EMHFWLYH3KDVHE
7RGHWHUPLQHWKHVDIHDQGUHFRPPHQGHG3KDVHGRVH53'RI$ 35LQFRPELQDWLRQ
ZLWKD]DFLWLGLQHDVGHWHUPLQHGE\GRVHOLPLWLQJWR[LFLWLHV'/7 V
3ULPDU\2EMHFWLYH3KDVH
7RGHWHUPLQHWKHSURSRUWLRQRISDWLHQWVZLWK 73PXWDQWP\HORLGQHRSODVPVZKRDUHLQ
FRPSOHWHUHPLVVLRQ DVPHDVXUHGE\WKHLQWHUQDWLRQDOZRUNLQJJURXSFULWHULD,:* 
6HFRQGDU\2EMHFWLYHV
7RGHWHUPLQHWKHGXUDWLRQRIUHVSRQVH
7RGHWHUPLQHWKHSURSRUWLRQRISDWLHQWVZLWK 73PXWDQWP\HORLGQHRSODVPVDOLYHDW
PRQWKV
7RGHWHUPLQHRYHUDOOEHVWUHVSRQVHUDWHVDVPHDVXUHGE\WKHLQW HUQDWLRQDOZRUNLQJJURXS
FULWHULD,:*
7RGHWHUPLQHLIPXWDQW 73YDULDQWDOOHOHIUHTXHQF\9$)RUSSURWHLQH[SUHVVLRQ
SUHGLFWVUHVSRQVHWR$35ZLWKD]DFLWLGLQH
7RGHWHUPLQHLISSURWHLQH[SUHVVLRQFRUUHODWHVZLWK 739$)
7RGHWHUPLQHLI$35ZLWKD]DFLWLGLQHWUHDWPHQWOHDGVWRPXW DQW73FORQDO
VXSSUHVVLRQ
7RGHWHUPLQHLI 73FORQDOVXSSUHVVLRQFRUUHODWHVZLWKRXWFRPHV
7RGHWHUPLQHLI$35WUHDWPHQWXSUHJXODWHVSWDUJHWJHQHV
7RGHWHUPLQHLI$35LQGXFHVUHDFWLYHR[\JHQVSHFLHV526S URGXFWLRQ
7RGHWHUPLQHWKHUDWHDQGWLPHW RDFXWHP\HORLGOHXNHPLD$0/ WUDQVIRUPDWLRQ
7RGHWHUPLQHWKHPHGLDQRYHUDOOVXUYLYDO26
7RGHWHUPLQHWKHPHGLDQOHXN HPLDIUHHVXUYLYDO/)6
7RGHWHUPLQHZKHWKHUUHFXUUHQWJHQHWLFPXWDWLRQVDUHSUHGLFWLYH RIUHVSRQVH

6WXG\
(QGSRLQWV3ULPDU\
3KDVHE'/7VRFFXUULQJLQWKHILUVWF\FOHVZHHNVDVGH ILQHGEHORZJUDGHG
DFFRUGLQJWRWKH1&,&7&$(9HUVLRQ 
3KDVH&5UDWHE\,:*FULWHULDDSSHQGL[% 
6HFRQGDU\ 
'XUDWLRQRIUHVSRQVHGHILQHGDVWKHWLPHEHWZHHQDFKLHYLQJUHVS RQVHDQGSURJUHVVLRQRI


GLVHDVH
26DWPRQWKV
3URSRUWLRQRIVXEMHFWVDFKLHYLQJKHPDWRORJLFDOLPSURYHPHQW+, SDUWLDOUHVSRQVH35
FRPSOHWHUHVSRQVH&5DQGRUPDUURZ&5P&5E\WKH,:* FULWHULDDSSHQGL[% 
3URSRUWLRQRIVXEMHFWVZKRREWDLQDUHVSRQVHDVGHILQHGE\,:* FULWHULDZLWKDEDVHOLQH
739$)Â•YHUVXVRUKLJKYHUVXVORZQXFOHDUSSURWHLQ H[SUHVVLRQ
&RUUHODWLRQRI 739$)ZLWKQXFOHDUSSURWHLQH[SUHVVLRQDVGHWHUPLQHGE\
LPPXQRKLVWRFKHPLVWU\,+&
3URSRUWLRQRIVXEMHFWVZKRDFKLHYHÂ•UHGXFWLRQLQ 739$)
3URJUHVVLRQIUHHVXUYLYDO3)6DQG26LQFORQDOUHVSRQGHUVÂ• UHGXFWLRQLQ 73
9$)YHUVXVQRQUHVSRQGHUV 
3URILOHH[SUHVVLRQRIJHQHVUHODWHGWRSPHGLDWHGVLJQDOWUDQ VGXFWLRQEHIRUHDQGDIWHU
$35WUHDWPHQW3URILOH526SURGXFWLRQEHIRUH DQGDIWHU$35WUHDWPHQW
$0/WUDQVIRUPDWLRQDFFRUGLQJWR: RUOG+HDOWK2UJDQL]DWLRQ:+2 FULWHULD
26

/)6
'HWHUPLQHUHFXUUHQWJHQHPXWDWLRQVLQ $6;/%&25%5$)&$/5&%/&(%3$&6)5
'107$(79(=+*$7$*1$6 ,'+,'+-$..,7.5$60 3/1)130
15$63'*)5$3'*)5%3+)37315$'581;6(7%36)% 60&$
60&656)67$*67$767$7E7(7738$):7 DQG=565DWVWXG\HQWU\
DQGVHULDOO\WKURXJKRXWWUHDWPHQWWRDVVHVVFKDQJHVLQVRPDWLF PXWDWLRQODQGVFDSH
(OLJLELOLW\
&ULWHULD,QFOXVLRQ&ULWHULD 
3DWLHQW KDV VLJQHG WKH ,QIRUPHG &RQVHQW ,&) DQG LV DEOH WR FR PSO\ ZLWK SURWRFRO
UHTXLUHPHQWV
3DWLHQWKDVDGHTXDWHRUJDQIXQFWLRQDVGHILQHGE\WKHIROORZLQJ ODERUDWRU\YDOXHV
D6HUXPFUHDWLQLQHÂ”[XSSHUOLPLWRIQRUPDO8/1
E7RWDOVHUXPELOLUXELQ [8/1RUWRWDOELOLUXELQÂ” [8/1ZLWK
GLUHFWELOLUXELQZLWKLQQRUPDOUDQJHLQSDWLHQWVZLWK ZHOOGRFXPHQWHG
*LOEHUWÂ¶V6\QGURPHRUKHPRO\VLVRUZKRUHTXLUHGUHJXODU EORRGWUDQVIXVLRQV
F$ODQLQHDPLQRWUDQVIHUDVH$/7DQGDVSDUWDWHDPLQRWUDQV IHUDVH
$67[8/1
$JHÂ•\HDUVDWWKHWLPHRIVLJQLQJWKHLQIRUPHGFRQVHQWIRUP 
'RFXPHQWHGGLDJQRVLVRIP\HORG\VSODVWLFV\QGURPH0'60'6P\ HORSUROLIHUDWLYH
QHRSODVP031FKURQLFP\HORPRQRF\WLFOHXNHPLD&00/E\:+2F ULWHULDRU
$0/ZLWKP\HOREODVWVUHIUDFWRU\DQHPLDZLWKH[FHVVEODV WVLQWUDQVIRUPDWLRQ


5$(%7E\)UHQFK$PHULFDQ%ULWLVK)$%FULWHULD
'RFXPHQWDWLRQRID 73JHQHPXWDWLRQE\QH[WJHQHUDWLRQVHTXHQFLQJ1*6EDVHGRQ
FHQWUDORUORFDOHYDOXDWLRQ
5HYLVHG,QWHUQDWLRQDO3URJQRVWLF6FRULQJ6\VWHP,3665FULWHU LDIRU,QWHUPHGLDWH+LJK
ULVNRU9HU\+LJKULVN
$Q(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS(&2*SHUIRUPDQFHVWDWXV VFRUHRIRULV
UHTXLUHG
,IRIFKLOGEHDULQJSRWHQWLDOQHJDWLYHSUHWUHDWPHQWXULQHRUV HUXPSUHJQDQF\WHVW
,I RI FKLOGEHDULQJ SRWHQWLDO PDOHV DQG IHPDOHV ZLOOLQJ WR XV H DQ HIIHFWLYH IRUP RI
FRQWUDFHSWLRQVXFKDVODWH[FRQGRPKRUPRQDOELUWKFRQWUROLQW UDXWHULQHGHYLFHRUGRXEOH
EDUULHUPHWKRGGXULQJFKHPRWKHUDS\WUHDWPHQWDQGIRUDWOHDVWV L[PRQWKVWKHUHDIWHU
 
 
 
 
 
 
 
 
([FOXVLRQ&ULWHULD
3DWLHQWKDVDNQRZQKLVWRU\RI+,9RUDFWLYHKHSDWLWLV%RUDF WLYHKHSDWLWLV&LQIHFWLRQ
WHVWLQJQRWPDQGDWRU\
3DWLHQWKDVDQ\RIWKHIROORZLQJFDUGLDFDEQRUPDOLWLHVDVGHW HUPLQHGE\WUHDWLQJ0'
DV\PSWRPDWLFFRQJHVWLYHKHDUWIDLOXUH
EP\RFDUGLDOLQIDU FWLRQÂ”PRQWKVSULRUWR HQUROOPHQW
FXQVWDEOHDQJLQDSHFWRULVGVHULRXVXQFRQWUROOHGFDUGLDFDU[LOCATION_006]\WKPLD
H47FÂ•PVHF
&RQFRPLWDQWPDOLJQDQFLHVRUSUHYLRXVPDOLJQDQFLHVZLWKOHVVWK DQD\HDUGLVHDVHIUHH
LQWHUYDODWWKHWLPHRIVLJQLQJFRQVHQW3DWLHQWVZLWKDGHTXDWH O\UHVHFWHGEDVDORUVTXDPRXV
FHOOFDUFLQRPDRIWKHVNLQRUDGHTXDWHO\UHVHFWHGFDUFLQRPDLQ VLWXHJFHUYL[PD\HQUROO
LUUHVSHFWLYHRIWKHWLPHRIGLDJQRVLV
3ULRUH[SRVXUHWRD]DFLWLGLQHGHFLWDELQHRULQYHVWLJDWLRQDOK\ SRPHWK\ODWLQJDJHQW
8VHRIF\WRWR[LFFKHPRWKHUDSHXWLFDJHQWVRUH[SHULPHQWDODJHQW VDJHQWVWKDWDUHQRW
FRPPHUFLDOO\DYDLODEOHIRUWKHWUHDWPHQWRI0'60'6031&00/ RU$0/ZLWKLQ
GD\VRIWKHILUVWGD\RIVWXG\GUXJWUHDWPHQW
1RFRQFXUUHQWXVHRIHU\WKURLGVWLPXODWLQJDJHQWV*&6)*0& 6)LVDOORZHGGXULQJVWXG\
H[FHSWLQFDVHVRIIHEULOHQHXWURS HQLDZKHUH*&6)FDQEHXVHG IRUVKRUWWHUP*URZWK
IDFWRUVPXVWEHVWRSSHGGD\VSULRUWRVWXG\
3DWLHQWVZLWKKLVWRU\RIDOORJHQH LFVWHPFHOOWUDQVSODQWDWLRQ 
3UHJQDQWZRPHQDUHH[FOXGHGIURPWKLVVWXG\EHFDXVH$35KDV QRWEHHQVWXGLHGLQ
SUHJQDQWVXEMHFWV%HFDXVHWKHUHLVDQXQNQRZQEXWSRWHQWLDOUL VNIRUDGYHUVHHYHQWVLQ
QXUVLQJLQIDQWVVHFRQGDU\WRWUHDWPHQWRIWKHPRWKHUZLWK$35 EUHDVWIHHGLQJVKRXOGEH
GLVFRQWLQXHGLIWKHPRWKHULVWUHDWHGZLWK$35




%DVHOLQH$VVHVVPHQW
ZLWKLQ
ZHHNVRIVWDUWLQJWUHDWPHQW
0HGLFDOKLVWRU\LQFOXGLQJ
DGLVHDVHFKDUDFWHULVWLFVVXFKDV:+2VXEW\SH,3665,366VFR UHSULRUWUHDWPHQWV
E(&2*SHUIRUPDQFHVWDWXV
F&RQFXUUHQWPHGLFDWLRQUHYLHZ
5RXWLQHSK\VLFDOH[DPLQDWLRQ(.*%RQHPDUURZH[DPLQDWLRQLQFOXGLQJF\WRPRUSKRORJ\F\WRJHQHW LFDVVHVVPHQWDQGIORZ
F\WRPHWU\DQDO\VLV
'RFXPHQWDWLRQRID 73JHQHPXWDWLRQE\1*6EDVHGR QFHQWUDORUORFDOHYDOXDWLRQ
/DERUDWRU\DVVHVVPHQWVÂ‡&%&ZLWKGLIIHUHQWLDOLQFOXGLQJSODWHOHWFRXQW
Â‡&OLQLFDOFKHPLVWULHVLQFOXGL QJ%81FUHDWLQLQHVRGLXPSRWDV VLXPDONDOLQHSKRVSKDWDVH$/7
$67WRWDOELOLUXELQDQGDOEXPLQÂ‡8ULQHRUVHUXPSUHJQDQF\WHVWIRUIHPDOHVRIFKLOGEHDULQJSRW HQWLDOZLOOEHSHUIRUPHGEHWZHHQ
6FUHHQLQJDQGILUVWGD\RIWUHDWPHQWRQVWXG\SULRUWRILUVWG RVHRIVWXG\PHGLFDWLRQ
5HYLHZDQGUHFRUGDQ\UHGEOR RGFHOODQGSODWHOHWWUDQVIXVLR QVIRUWKHSULRUZHHNV
7UHDWPHQW
SODQ7UHDWPHQWZLOOEHDGPLQLVWHUHGRQDQRXWSDWLHQWEDVLV5HSRUWH GDGYHUVHHYHQWVDQGSRWHQWLDO
ULVNVDUHGHVFULEHGLQ6HFWLRQ$SSURSULDWHGRVHPRGLILFDWLR QVIRU$35DUHGHVFULEHGLQ
6HFWLRQ1RLQYHVWLJDWLRQDORU FRPPHUFLDODJHQWVRUWKHUDSL HVRWKHUWKDQWKRVHGHVFULEHG
EHORZPD\EHDGPLQLVWHUHGZLWKWKHLQWHQWWRWUHDWWKHSDWLHQW
 VGLVHDVH$35ZLOOEH
VXSSOLHGE\$SUHD

$35ZLOOEHDGPLQLVWHUHGDVDKRXULQWUDYHQRXVLQIXVLRQG DLO\RQGD\VIRUHDFKGD\
F\FOH$]DFLWLGLQHZLOOEHJLYHQD WWKHVWDQGDUGGRVHRIPJPRYHUGD\VFRQVHFXWLYH
GD\VRULHGD\VDQGDVDVXEFXWDQHRXV LQMHFWLRQRULQWUDYHQRXVLQIXVLRQ
$PD[LPXPRIVXEMHFWVZLOOEHWUHDWHG6HHVWXG\FDOHQGDUIR UDVVHVVPHQWRQVWXG\
'HILQLWLRQRI
'/73DWLHQWVZLOOEHHYDOXDWHGIRU'/7VGXULQJWKHOHDGLQSKDVHDQ GILUVWF\FOHRIFRPELQDWLRQ
WKHUDS\LHZHHNVIRUSXUSRVHRIGHFLGLQJWKHGRVHIRUQH[ WFRKRUWVHH7DEOHEXW'/7V
ZLOOFRQWLQXHWREHHYDOXDWHGDQGUHSRUWHGWKURXJKDOOF\FOHVR QVWXG\'/7LVGHILQHGDVIROORZV
EDVHGRQWKH&7&$(Y
7UHDWPHQWUHODWHGQRQKHPDWRORJ LFDO&7&$(JUDGHWR[LFLW\W KDWOHDGWRGRVHPRGLILFDWLRQ
RUZLWKGUDZDO
$EVROXWHQHXWURSKLOFRXQW$1&QRWUHFRYHULQJWR!Â—/E\G D\RIDF\FOHLQWKHDEVHQFH
RIDFWLYHOHXNHPLDP\HORG\VSODVLDZLOOEHFRQVLGHUHGD'/7
*UDGHPHWDEROLFHOHFWURO\WHDEQRUPDOLWLHVWKDWDUHQRWFOLQL FDOO\VLJQLILFDQWDQGDUH
DGHTXDWHO\FRQWUROOHGZLWKLQKRXUVDUHQRWWREHFRQVLGHUHG '/7
*UDGHQDXVHDYRPLWLQJGLDU[LOCATION_006]HDRU&16WR[LFLW\WKDWGRHVQRW UHVROYHZLWKLQGD\VGHVSLWH


WUHDWPHQWLQWHUUXSWLRQDQGPD[LPXPPHGLFDOWKHUDS\ZLOOEHFRQV LGHUHGD'/7
'RVHGHOD\
PRGLILFDWLRQV'RVHGHOD\VPRGLILFDWLRQVDUHDOOR ZHGDVGHVFULEHGLQVHFWLRQ 
'XUDWLRQRI
7KHUDS\6XEMHFWVZLOOEHWUHDWHGIRUDW RWDORIF\FOHV )RUVXEMHFWV UHVSRQGLQJRUZKRKDYHVWDEOH
GLVHDVHIROORZLQJF\FOHWUHDWPHQWPD\FRQWLQXHXQWLORQHRI WKHIROORZLQJFULWHULDDSSOLHV
x,QWHUFXUUHQWLOOQHVVWKDWSUHYHQWVIXUWKHUDGPLQLVWUDWLRQRIW UHDWPHQW
x8QDFFHSWDEOHDGYHUVHHYHQWV
x3DWLHQWGHFLGHVWRZLWKGUDZIURPWKHVWXG\RU
x*HQHUDORUVSHFLILFFKDQJHVLQWKHSDWLHQW
VFRQGLWLRQUHQGHUW KHSDWLHQWXQDFFHSWDEOHIRU
IXUWKHUWUHDWPHQWLQWKHMXGJPHQWRIWKHLQYHVWLJDWRU
x(YLGHQFHRIGLVHDVHSURJUHVVLRQE\WKH,:*FULWHULDVHH$ SSHQGL[%QRWDSSOLFDEOH
DWERQHPDUURZHYDOXDWLRQDWGD\RIOHDGLQSKDVH
6XEMHFWVZKRZLVKQRWWRFRQWLQXHWUHDWPHQWDWWLPHRIGLVHDVH DVVHVVPHQWDWHQGRIF\FOHZLOO
FRPSOHWHWKHLUHQGRIWUHDWPHQWYLVLWXSRQFRPSOHWLRQRIF\FOH 
'XUDWLRQRI
)ROORZ8S6XEMHFWVZLOOEHIROORZHGDVSHU FDOHQGDURQWUHDWPHQWIRUF\ FOHV)LJXUH$IWHUF\FOHV
VXEMHFWVZKRFRQWLQXHRQVWXG\ZLOOEHIROORZHGPRQWKO\2IIWU HDWPHQWGDWDRQ$0/
WUDQVIRUPDWLRQDQGRYHUDOOVXUY LYDOZLOOEHXSGDWHGHYHU\PRQ WKVRUXQWLOGHDWKZKLFKHYHU
RFFXUVILUVW6XEMHFWVUHPRYHGIURPWKHVWXG\IRUXQDFFHSWDEOH DGYHUVHHYHQWVZLOOEHIROORZHG
XQWLOUHVROXWLRQRUVWDELOL]DWLRQRIWKHDGYHUVHHYHQW
&ULWHULDIRU5HPRYDOIURP6WXG\
6WXG\GUXJWUHDWPHQWFDQFRQWLQXHIRUVXEMHFWVUHFHLYLQJFOLQLF DOEHQHILWXQOHVVRQHRUPRUH
ZLWKGUDZDOFULWHULDDUHPHWRU DWWKHVXEMHFWÂ¶VGLVFUHWLRQRU LIWKHVWXG\LVWHUPLQDWHG
6XEMHFW&RPSOHWLRQ$VXEMHFWZLOOEHFRQVLGHUHGWRKDYHFRPSOHWHGWKHVWXG\LI WKHVXEMHFWPHHWV
DWOHDVWRIWKHIROORZLQJFULWHULD
7KHVXEMHFWKDVSURJUHVVLYHGLVHDVH7KHVXEMHFWGLHGGXULQJWKHVWXG\
7KHVXEMHFWH[SHULHQFHGDW UHDWPHQWUHODWHG$(WKDWOHG WRZLWKGUDZDOIURPWKHVWXG\
7KHVXEMHFWVWDUWVQHZWUHDWPHQWIRUWKHLUXQGHUO\LQJG LVHDVH0'6&00/$0/
6XEMHFW:LWKGUDZDOIURP6WXG\$VXEMHFWPD\YROXQWDULO\ZLWKGUDZIURPVWXG\PHGLFDWLRQRU ZLWKGUDZFRQVHQWIURPWKH
VWXG\DWDQ\WLPH7KHLQYHVWLJDWRUPD\DOVRDWKLVRUKHU GLVFUHWLRQGLVFRQWLQXHDVXEMHFW
IURPSDUWLFLSDWLQJLQWKHVWXG\DWDQ\WLPH7KHLQYHVWLJDW RUDQGRUGHVLJQDWHGVWDIIZLOOUHFRUG
WKHGDWHDQGWKHUHDVRQIRUVXEMHFWZLWKGUDZDOIURPWKHVWX G\
6XEMHFW:LWKGUDZDOIURP6WXG\0HGLFDWLRQ
,IWKHVXEMHFWLVSHUPDQHQWO\ZLWKGUDZQIURPWUHDWPHQWZLWK VWXG\PHGLFDWLRQEXWGRHVQRW
ZLWKGUDZFRQVHQWWKHLQYHVWLJDWRUPXVWPDNHHYHU\HIIRUWW RKDYHWKHVXEMHFWFRPSOHWHDOO


ZLWKGUDZDODVVHVVPHQWVDWWKHWLPHRIZLWKGUDZDODQGFRPSO HWHDOOVFKHGXOHGIROORZXS
YLVLWV

7UHDWPHQWZLWKVWXG\PHGLFDWLRQPXVWEHGLVFRQWLQXHGLI:LWKGU DZDO&ULWHULD UU
(YLGHQFHRI'LVHDVHSURJUHVVLRQ DFFRUGLQJWR,:*FULWHULD VHH$SSHQGL[%QRWDSSOLFDEOH
DWERQHPDUURZHYDOXDWLRQDWGD\RIOHDGLQSKDVH
$VXEMHFWEHFRPHVSUHJQDQW
$VXEMHFWLVVLJQLILFDQWO\QRQFRPSOLDQWZLWKWKHUHTXLUHPHQWV RIWKHSURWRFRO
$VXEMHFWKDVDQDGYHUVHH[SHULHQFHWKDWZRXOGLQWKHLQYHVWLJ DWRUÂ¶V
MXGJPHQWPDNHFRQWLQXHGSDUWLFLSDWLRQLQWKHVWXG\DQXQDFFHSW DEOHULVN
$VXEMHFWZLWKGUDZDOVFRQVHQW
)ROORZXSRQ
VWXG\6HHFDOHQGDU6HFWLRQ


7KLVUXOHKDVWKHIROORZLQJRSHUDWLQJFKDUDFWHULVWLFVSRZ HUZLWKDOSKD XQGHUWKHQXOO
K\SRWKHVLVWKDWWKHSURSRUWLRQRISDWLHQWVDFKLHYLQJ&5LVÂ” YHUVXVWKHDOWHUQDWLYH
K\SRWKHVLVWKDWLWLVÂ•7K LVGHVLJQKDVDSUREDELOLW\RI HDUO\WHUPLQDWLRQHTXDOWRLIWKH
WUXH&5UDWHLV

1XPEHURI3DWLHQWV3ODQQHG  
7KHQXPEHURISDWLHQWVHQUROOHGZLOOGHSHQGRQWKHQXPEHURIGR VHOHYHOVHYDOXDWHGEHIRUH
UHDFKLQJ'/77KUHHWRHYDOXDEOH SDWLHQWVZLOOEHHQWHUHGSHU GRVHOHYHO,WLVDQWLFLSDWHGWKDW
XSWRHYDOXDEOHSDWLHQWVFDQ EHWUHDWHGLQWKH3KDVHESRUW LRQRIWKHVWXG\8SWR
DGGLWLRQDOHYDOXDEOHSDWLHQWVZLOOEHWUHDWHGDWWKHOHYHORIW KH07'LQWKH3KDVHSRUWLRQRIWKH
WULDO7KHPD[LPXPWRWDODFFUXDOLVSDWLHQWV

$QDO\VHVWRDGGUHVVVWXG\REMHFWLYHV
7RDGGUHVVWKHSULPDU\REMHFWLYHIRU3KDVHEZHZLOODSSO\WK HGHVLJQDERYH
7RDGGUHVVWKHSULPDU\REMHFWLYHIRU3KDVHZHZLOODSSO\WKH 6LPRQÂ¶VWZRVWDJHPLQLPD[
GHVLJQDERYH
$QDO\VLVRIWKHIROORZLQJVHFRQGDU\HQGSRLQWVZLOOEHRIH[SORU DWRU\QDWXUH 
'XUDWLRQRIUHVSRQVHGHILQHGDVWKHWLPHEHWZHHQDFKLHYLQJUHVS RQVHDQGSURJUHVVLRQRIGLVHDVH
26DWPRQWKV 
3URSRUWLRQRIVXEMHFWVDFKLHYLQJKHPDWRORJLFDOLPSURYHPHQW+, SDUWLDOUHVSRQVHFRPSOHWH
UHVSRQVH&5DQGRUPDUURZ&5P&5E\WKH,:*FULWHULD VHHDSSHQGL[% 
3URSRUWLRQRIVXEMHFWVZKRREWDLQDUHVSRQVHDVGHILQHGE\,:* FULWHULDZLWKDEDVHOLQH
739$)Â•YHUVXVRUKLJKYHUVXVORZQXFOHDUSSURWHLQ H[SUHVVLRQ
&RUUHODWLRQRI 739$)ZLWKQXFOHDUSSURWHLQH[SUHVVLRQDVGHWHUPLQHGE\,+&
3URSRUWLRQRIVXEMHFWVZKRDFKLHYHÂ•UHGXFWLRQLQ 739$)
3URJUHVVLRQIUHHVXUYLYDO3)6DQG26LQFORQDOUHVSRQGHUVÂ• UHGXFWLRQLQ 739$)
YHUVXVQRQUHVSRQGHUV 
3URILOHH[SUHVVLRQRIJHQHVUHODWHGWRSPHGLDWHGVLJQDOWUDQ VGXFWLRQEHIRUHDQGDIWHU$35
WUHDWPHQW
3URILOH526SURGXFWLRQEHIRUH DQGDIWHU$35WUHDWPHQW
$0/WUDQVIRUPDWLRQDFFRUGLQJWR: RUOG+HDOWK2UJDQL]DWLRQ:+2 FULWHULD
26
/)6
'HWHUPLQHUHFXUUHQWJHQHPXWDWLRQVLQ $6;/%&25%5$)&$/5&%/&(%3$&6)5
'107$(79(=+*$7$*1$6 ,'+,'+-$..,7.5$60 3/1)130
15$63'*)5$3'*)5%3+)37315$'581;6(7%36)% 60&$
60&656)67$*67$767$7E7(7738$):7 DQG=565DWVWXG\HQWU\
DQGVHULDOO\WKURXJKRXWWUHDWPHQWWRDVVHVVFKDQJHVLQVRPDWLF PXWDWLRQODQGVFDSH


2%-(&7,9(6

3ULPDU\2EMHFWLYH3KDVHE
7RGHWHUPLQHWKHVDIHDQGUHFR PPHQGHG3KDVHGRVH53'RI$3 5LQ
FRPELQDWLRQZLWKD]DFLWLGLQHDV GHWHUPLQHGE\ GRVHOLPLWLQJWR[ LFLWLHV'/7V
3ULPDU\2EMHFWLYH3KDVH
7RGHWHUPLQHWKHSURSR UWLRQRISDWLHQWVZLWK 73PXWDQWP\HORLGQHRSODVPVZKRDUH
LQFRPSOHWHUHPLVVLRQDVPHDVXUH GE\WKHLQWHUQDWLRQDOZRUNLQJ JURXSFULWHULD,:*
6HFRQGDU\2EMHFWLYHV
7RGHWHUPLQHWKHGXU DWLRQRIUHVSRQVH
7RGHWHUPLQHWKHSURSR UWLRQRISDWLHQWVZLWK 73PXWDQWP\HORLGQHRSODVPVDOLYHDW
PRQWKV
7RGHWHUPLQHRYHUDOOEHVWUHVSRQVH UDWHVDVPHDVXUHGE\WKHLQW HUQDWLRQDOZRUNLQJJURXS
FULWHULD,:*
7RGHWHUPLQHLIPXWDQW73YDULDQ WDOOHOHIUHTXHQF\9$)RUS SURWHLQH[SUHVVLRQ
SUHGLFWVUHVSRQVHWR$ 35ZLWKD]DFLWLGLQH
7RGHWHUPLQHLISSURWHLQH[SUH VVLRQFRUUHODWHVZLWK739$) 
7RGHWHUPLQHLI$35 ZLWKD]DFLWLGLQHWUHDWPHQWOHDGVWRPXW DQW73FORQDO
VXSSUHVVLRQ
7RGHWHUPLQHLI73F ORQDOVXSSUHVVLRQFRU UHODWHVZLWKRXWFRPH V
7RGHWHUPLQHLI$35 WUHDWPHQWXSUHJXODW HVSWDUJHWJHQHV
7RGHWHUPLQHLI$35LQGXFHVU HDFWLYHR[\JHQVSHFLHV526S URGXFWLRQ
7RGHWHUPLQHWKHUDWHDQGWLPHW RDFXWHP\HORLGOHXNHPLD$0/ WUDQVIRUPDWLRQ
7RGHWHUPLQHWKHPHGLDQ RYHUDOOVXUYLYDO26
7RGHWHUPLQHZKHWKHUUHFXUUHQWJ HQHWLFPXWDWLRQV DUHSUHGLFWLYH RIUHVSRQVH


%$&.*5281'

0\HORG\VSODVWLF6\QGURPHV

0\HORG\VSODVWLFV\QGURPHV0'6 DUHDKHWHURJHQHRXVJURXSRIQH RSODVPVDULVLQJIURPD
FORQDOKHPDWRSRL HWLFSUHFXUVRU0'6LVFKDUDFWHUL]HGFOLQLFDOO\ E\F\WRSHQLDVDQGDWHQGHQF\
WRWUDQVIRUPWRDFXWHP\HORLGOHXNHPLD$0/3URJQRVWLFVFRULQJV\VWHPVKDYHEHHQ


GHYHORSHGWRKHOSVWU DWLI\SDWLHQWVEDVH GRQSUHGLFWHGVXUYLYDO DQGSURJUHVVLRQWR$0/,Q
SUDFWLFHWUHDWPHQWGHFLVLRQVDUH PDGHE\JURXSLQJSDWLHQWVZLW K0'6LQWRORZHUDQGKLJKHUULVN
VXEJURXSVDVGHILQHGE\FOLQLFDO SURJQRVWLFVFRULQJV\VWHPV6S HFLILFDOO\WKH,QWHUQDWLRQDO
3URJQRVWLF6FRULQJ6\VWHP,366DQGLWVPRUHPRGHUQYHUVLRQW KHUHYLVHG,3665,366
UHSUHVHQWWKHPRVWZLGHO\ XVHGFOLQLFDOSURJQRVWLFWRROV7KRVHSDWLHQWVWKDWI DOOLQWKHKLJKHU
ULVNJURXSKDYHDQH[SHFWHGVXUYL YDORIOHVVWKDQPRQWKVLI OHIWXQWUHDWHGDQGSURJUHVVWR
$0/JUHDWHUWKDQRIWKHWLPH
730XWDWLRQVLQ0'6DQG$0/

7KHDGYHQWRIQH[WJHQHUDWLRQVH TXHQFLQJ1*6KDVSURYLGHGDU DSLGDQGHIILFLHQ WSODWIRUPIRU
JHQRPHVWXGLHVWKDWKDVUHYROX WLRQL]HGWKHGLDJQRVWLFSURJQRVW LFDQGWKHUDSHXWLFUHDOPVRI
P\HORLGPDOLJQDQFLHV
&XUUHQW1*6P\HORLGSDQHOVLQF RUSRUDWHJHQHVDQGFDQLG HQWLI\
PXWDWLRQVLQWKHYDVWP DMRULW\RISDWLHQWV,Q0'6PXWDWLRQVRI $6;/(79(=+581;
DQG73ZHUHIRXQGWREHLQGHSHQGHQWO\D VVRFLDWHGZLWKGHFUHDVHGVXUYL YDO2IWKHVHUHFHQW
LQYHVWLJDWLRQVKDYHV XJJHVWHGWKDWWKHPX WDWLRQDOVWDWXVRI 73LVWKHPRVWLPSRUWDQWQHJDWLYH
SURJQRVWLFIDFWRULQ0'6SDWLHQWV 7RGDWHWKHRQO\GLVHDVHPR GLI\LQJDJHQWVLQ0'6LQFOXGH
OHQDOLGRPLGHLQSDWLHQWVZLW KLVRODWHGGHOHWL RQRITGHOT DQGD]DFLWLGLQHD'1$
PHWK\OWUDQVIHUDVH'107LQKLELWRUK\SRPHWK\ODWLQJDJHQW+0$ LQ0'6SDWLHQWVZLWK
KLJKHUULVNGLVHDVHLHLQWHUPHGLDWHKLJKULVNE\,366DQG KLJKYHU\KLJKE\5,366
/HQDOLGRPLGHZDVDSSURYHGED VHGRQWKH0'6WULDOZLWKR IGHOTSDWLHQWVDFKLHYLQJ
WUDQVIXVLRQLQGHSHQGH QFHDQGRISDWLHQWVZLWKFRPSOHWHF\WR JHQHWLFUHVSRQVH+RZHYHU
SULPDU\UHVLVWDQFHWROHQDOLGR PLGHKDVEHHQGLUHFWO\OLQNHGWR 73PXWDWLRQZKLFKRFFXUVLQ
RISDWLHQWV:KHUHDVSDUWLDOF\WRJHQHWLF UHVSRQVHVRFFXULQXSWRRIS DWLHQWV73
PXWDWHGGHOTSD WLHQWVRQO\KDYHF\WRJHQHWLFUHVSRQVHVLQ RIFDVHV)RUKLJKHUULVN
0'6SDWLHQWVD]DFLWLGLQHUHSUHV HQWVWKHVWDQGDUGRIFDUHEDVHG RQWKH$=$WULDOWKDW
GHPRQVWUDWHGDVXUYLYDODGYDQWDJHIRUD]DFLWLGLQHZKHQFRPSDUHG ZLWKLQGXFWLRQFKHPRWKHUDS\
ORZGRVHF\WDUDELQHRUEHVWVXSSRUWLYHFDUHPRQWKVYHUVX VPRQWKVS$
UHFHQWVWXG\LQ0'6VKRZHGVWURQJDVVRFLDWLRQRI 73PXWDWLRQZLWKSRRURXWFRPHLQ
D]DFLWLGLQHWUHDWHGSDWLHQWV,QDGGLWLRQ%HMDUDQGFROOHDJXH VUHFHQWO\FRQILUPHGGHFUHDV HG26
LQ73PXWDWHG0'6SDWLHQWVWUHDWHGZ LWK+0$ZLWKRXWHIIHFWRQUHVSRQ VHUDWHV/DVWO\
PXWDWLRQVRI 73VWURQJO\SUHGLFWIRUODFNRIEH QHILWWRDOORJHQHLFERQHPDUURZ WUDQVSODQWDWLRQ


ZKLFKUHSUHVHQWVWKHRQO\FXUDWLY HRSWLRQIRUSDWLHQWVZLWK0'67KLVVWXG\KLJKOLJKWVWKH
SURJQRVWLFLPSRUWDQFHRI 73PXWDWLRQVDVSDWLHQWVZLW KFRPSOH[NDU\RW\SHZLWKRXW 73
PXWDWLRQKDGVLPLODUVXUYLYDOWRSDWLH QWVZLWKQRUPDONDU\RW\SH 
:HKDYHUHFHQWO\DQDO\]H GRXURZQH[SHULHQFHRQPROHFXODUO \SURILOHGSDWLHQWVDW0RIILWW
&DQFHU&HQWHUDQGLGHQWLILHGW KDWWKHFORQDOEXUGHQRUYDULDQW DOOHOHIUHTXHQF\9$)KDG
VLJQLILFDQWLPSDFWRQFOLQLFDOSKH QRW\SHDQGPRUHLPSRUWDQWO\I XUWKHUVWUDWLILHGSURJQRVLVRYHU
ELQDU\PXWDWLRQDODQDO\VLVDO RQHDQGRUFOLQLFDOSURJQRVWLFPRG HOV6SHFLILFDOO\0'6SDWLHQWV
ZLWKD739$)!KDGDPHGLDQRYHUDOO VXUYLYDO26RIGD\VYHUVX VDQ26WKDWZDV
QRWUHDFKHGLQSDWLHQWVZLWK9$) KD]DUGUDWLR+5 3 ZLWKYDOLGDWLRQLQDQ
LQGHSHQGHQWFRKRUW+5 3 2YHUDOO 73PXWDQW0'6DQG$0/ SDWLHQWVKDYHD
PHGLDQ26UDQJLQJIURPPRQW KVZLWKPRQWKVUHSUHVHQWLQJWK HEHVWHVWLPDWHZKHQ
UHVWULFWLQJWR0'6DQGROLJREO DVWLF$0/EODVWV7RJHWKHUWKHVH GDWDKLJKOLJKW
WKHGLVPDORXWFRPHVRI 73PXWDQWSDWLHQWVDQGWKHGLUHQH HGIRUWKHGHYHORSPHQWRIQRYHO 
WKHUDSHXWLFVWUDWHJLHVSDUWLF XODUO\LQWKLVSDWLHQWSRSXODWLRQ 

$35

5HVWRUDWLRQRIZLOGW\S HIXQFWLRQIURPPXWDQWRURWKHUZLVHG\VI XQFWLRQDOXQIROGHGSKDVEHHQ
VXJJHVWHGWREHDQHIILFLHQWVWUDWHJ\IRUVHOHFWLYHHOLPLQDWLRQ RIWXPRUFHOOV$PROHFXOHWKDW
UHDFWLYDWHVPXWDQWSVKRXOGEHOH VVHIIHFWLYHLQFHOOVZLWKZ LOGW\SHSEHFDXVHWKHZLOGW\SH
SURWHLQLVIRXQGDWORZOHYHOVL QWKHDEVHQFHRIVWUHVV,QFRQ WUDVWPXWDQWSRIWHQDFFXPXODWHV
DWKLJKOHYHOVDQGLVDOUHDG\Â³S UHDFWLYDWHGÂ´E\SRVWWUDQVODWLR QDOPRGLILFDWLRQVL QWXPRUFHOOVGXH
WRFRQVWLWXWLYHVWUHVVVLJQDOLQJ LHRQFRJHQHDFWLYDWLRQ'1 $GDPDJHDQGK\ SR[LD7KLVKDV
EHHQFRPPRQO\REVHUYHGLQ0'6ZLWK 73PXWDWLRQDQGZHKDYHU HFHQWO\VKRZQWKDW 73
9$)GLUHFWO\FRUUHODWHVZLWKS H[SUHVVLRQLQDQDO\VLVRIERQH PDUURZIURP 73PXWDQW
SDWLHQWV7KHUHIRUHPXWDQWSUHDFWLYD WLRQVKRXOGWULJJHUUREXVWDSR SWRVLVLQWXPRUFHOOVEXW
QRWLQQRUPDOFHOOV
:LPDQDQGFROOHDJXHVLGHQWLILH G$35DOVRFDOOHG35,0$ LQDFHOOXODUVFUHHQIRU
FRPSRXQGVWKDWLQGXFHDSRSWRVLVSU HIHUHQWLDOO\LQKXPDQWXPRUF HOOVH[SUHVVLQJH[RJHQRXV
PXWDQWS7KHHIIHFWRI$35ZDVPRU HSURQRXQFHGLQ$0/FHOOVZLWKK RPR]\JRXV
73GHOHWLRQVWKDQLQZLOGW\SH 73FHOOVZKLOHFRPPRQO\XVHGD QWLOHXNHPLFGUXJVVKRZHG


WKHRSSRVLWHSDWWHUQEH LQJOHVVSURQRXQFHGLQ$0/FHOOVZLWKD EQRUPDOFKURPRVRPH7KH
RSWLPL]DWLRQSURJUDPRIWKHO HDGFRPSRXQG$35UHVXOWHGLQW KHLGHQWLILFDWLRQRIWKH
VWUXFWXUDODQDORJXH$35$SUHD Â¶VFDQGLGDWHGUXJLQFOLQLFDO GHYHORSPHQW$35KDV
PRUHGUXJOLNHSURSHUWLHVLQF RPSDULVRQWR$35HJEHLQJ PRUHSRWHQWDQGVKRZLQJEHWWHU
FHOOXODUSHUPHDELOLW\

0HFKDQLVPRIDFWLRQRI$35

$35OLNHWKHSDUHQWFRPSRXQG$ 35LVDSURGUXJZKLFK XQGHUSK\VLRORJLFDO
FRQGLWLRQVLVVSRQWDQHRXVO\FRQYH UWHGWRPHWK\OHQHTXLQXFOLGLQR QH04D0LFKDHODFFHSWRU
WKDWELQGVFRYDOHQWO\WRF\VWHLQHVLQPXWDQWS7UDQVIHURI04PRGLILHGPXWDQWSSURWHLQ
LQWRWXPRUFHOOVODFNLQJSL QGXFHGPDVVLYHDSRSWRVLVLQGLFDW LQJWKDWFRYDOHQWELQGLQJRI04
SHUVHLVVXIILFLHQWWRDFW LYDWHPXWDQWSDQGLQGXFHDSGH SHQGHQWELRORJLFDOUHVSRQVH7KHVH
DQGRWKHUH[SHULPHQWVGLUHFWO\O RRNLQJDWWKHFRQIRUPDWLRQDOVW DWHRISSURWHLQKDYHFRQILUPHG
WKDWELQGLQJRI04SXVKHVXQIROGH GPXWDQWRUZLOGW\SHSWRZD UGVDIXQFWLRQDOZLOGW\SH
FRQIRUPDWLRQ04LVDÂµVRIWÂ¶HO HFWURSKLOHKHQFHVWURQJO\SUHIH UULQJÂµVRIWÂ¶QXFOHRSKLOHVVXFKDV
WKLROV2QFHIRUPHGIURP$3504FRXOGSRWHQWLDOO\ELQGWR F\VWHLQHVLQPDQ\SURWHLQVLQ
WKHFHOO+RZHYHUYDULRXVIDFW RUVPD\OLPLWWKHQXPEHURISURW HLQWDUJHWVLQFOXGLQJDFFHVVLELOLW\
RIWKHWKLROQXFOHRSKLOLF LW\RIWKHVXOIXUDQGVWUXFWXUDOIOH [LELOLW\RIWKHWDUJHWHGSURWHLQGRPDLQ

7KLRUHGR[LQUHGXFWDVH7U[5 ZDVLGHQWLILHGDVDWDUJHWRI0 4SRWHQWLDOO\FRQWULEXWLQJWRWKH
DQWLFDQFHUHIIHFW04FRQYHUWVWKLVHQ]\PHIURP DUHGXFWDVHWRDQR[LGDVHWKDWF DQSURGXFH
UHDFWLYHR[\JHQVSHFLHV5267 KLVPD\FRQWULEXWHWR$35L QGXFHGFHOOGHDWKDQG
SUREDEO\DFFRXQWVDWOHDVWL QSDUWIRUWKHREVHUYHGHIIHFWVR I$35LQ 73QXOOFDQFHUFHOOV
)XUWKHULQYLWURH[SHULPHQWVKDYHVKRZ QWKDW04UHDGLO\UHDFWVZLWKJOXWDWKLRQH DFHQWUDO
PROHFXOHLQWKHFHOOXODUUHGR[V\VWHP7KXV$35YLD04KDVHIIHFWVWKDWOHDGWR
LPSDLUPHQWRIWKHWXPRUFHOOVFDS DFLW\WRKDQGOHR[LGDWLYHVWUH VVLQFOXGLQJGHSOHWLRQRI
JOXWDWKLRQH,QWXPRUFHOOVWKHUHGR[V \VWHPLVSXVKHGWRWKHOLPLWRILW VFDSDFLW\ZKLOHFRSLQJ
ZLWKHQKDQFHGR[LGDWLYHVWUHVV FRPSDUHGZLWKQRUPDOFHOOVPDNL QJWKHUHGR[V\VWHPDQ
$FKLOOHVÂ¶KHHORIWXPRUFHOOV7 KLVVHWRISURSHUWLHVFRQVWLWXW HVV\QWKHWLFDOO\OHWKDOWDUJHWVZKLFK
PD\EHXWLOL]HGWRVHOHFWLYHO\ NLOOWXPRUFHOOV7KHGXDODFWLY LW\RI$35UHVWRULQJZWS
IXQFWLRQRIPXWDQWSDQGLQFUHDVLQ JR[LGDWLYHVWUHVVLVLOOXV WUDWHGLQ)LJXUH


SDWLHQWVZHUHDFXWHP\HORLGOH XNHPLD$0/S DWLHQWVSURVWD WHFDUFLQRPDSDWLHQWVQRQ
+RGJNLQÂVO\PSKRPD1+/SDWLH QWVFKURQLFO\PSKRF\WLFOHXN HPLD&// SDWLHQWVDQG
PXOWLSOHP\HORPD00 SDWLHQW(LJKWHHQSDWLHQWVFRPSO HWHGWKHVWXG\LHFRPSOHWHG
WKHGD\YLVLWDQGSDWLHQWVZH UHSUHPDWXUHO\GLVFRQWLQXHG 
,QUHJDUGVWRDFWLYLW\W KHDSRSWRVLVSDWWH UQLQSDWLHQWV ZLWKKHPDWRORJLFD OPDOLJQDQFLHV
VKRZHGFHOOF\FOHFKDQJHVFRPSDWLEOHZLWKFHOOF\FOHDUUHVWLQ DOOSDWLHQWV ZLWKQRQ7FHOO
PDOLJQDQF\$OVRRWKHUDSRSWRVLVPDUNHUVZHU HDIIHFWHGVXFKDVLQFUHDVHG VWDLQLQJIRU
$QQH[LQ9XSUHJXODWLRQRI%$;% FODVVRFLDWHG;SURWHLQ1 2;$DQG380$H[SUHVVLRQ
DQGXSUHJXODWLRQRI'F5GHFR\UH FHSWRUDPDUNHUFRQVLGHUH GWREHDVVRFLDWHGZLWK
VHQHVFHQFH7KHRQHUHVSRQGLQJ SDWLHQWLQWKHL QLWLDOSKDVH FOLQLFDOWULDOZDVWKHRQO\ 73
PXWDQW$0/SDWLHQW6SHFLILFDOO\ WKLVSDWLHQWKDGDUHGXFWLRQ RIEODVWFHOOFRXQWIURPWR
DQGVKRZHGDFWLYDWLRQRISWDUJHWVVXSSRUWLQJLQYLYRDFW LYLW\
3KDVH,,,&OLQLFDO6WXG\$3 5GRVHGHHVFDODWLRQ

7KLVZDVDPXOWLFHQWHURSHQO DEHOQRQFRPSDUDWLYHSKDVH, GRVHGHHVFDODWLQJVWXG\RI$35
LQIXVLRQVLQSDWLHQWVZLWKUHIUD FWRU\KHPDWRORJLFPDOLJQDQF LHV,QWKLVVWXG\$PHQGPHQW
1RDORQJHULQIXVLRQWLPHZDV DSSOLHGUHVXOWLQJLQDQLQFUH DVHGH[SRVXUHRI$35
,Q
$PHQGPHQW1RWKHREMHFWLYHZD VWRLQFUHDVHWKHNQRZOHGJHRI WKHRSWLPDOZD\WRDGPLQLVWHU
$35DQGVWXG\WKHVDIHW\DQGW ROHUDELOLW\DVZHOODVWKHSK DUPDFRNLQHWLF 3.SURILOHRI
$357HQSDWLHQWVZLWKDFXWHP\H ORLGOHXNHPLD$0/RUFKUR QLFO\PSKRF\WLFOHXNHPLD
&//ZHUHSODQQHGIRUHQUROPHQW 7KHWUHDWPHQWVFKHGXOHZDV FRQVHFXWLYHGD\VZLWK$35
ZLWKWKHPRGLILHGGRVLQJUHJLPHQRIDVWDUWERRVWLQJLQIXVL RQRIPJNJGXULQJPLQ
IROORZHGE\DQPJNJLQIXVLRQIRUKRXUV,IWR[LFLW\ZD VVKRZQWKHGRVHZDVWREH
GHFUHDVHGWR'RVHOHYHOP JNJIRUPLQ>LQIXVLRQUDWH PJNJK@IROORZHGE\
PJNJ>LQIXVLRQUDWHPJN JK@IRUKRXUVRQWKHGLVFUH WLRQRIWKHLQYHVWLJDWRUDQGRUWKH
6WXG\%RDUG2XWRIWKH $0/SDWLHQWVZLWK 73PXWDWLRQERWKKDGDEO DVWUHGXFWLRQRQH
FRQVWLWXWLQJDUHVSRQVHDFFRUG LQJWRWKHUHVSRQVHFULWHULRQ2QWKHORZHUGRVHRIPJNJ
WKHUHZHUHQR'/7VRU6$(V2YHUD OOLQWKLVVWXG\WKHUHZHUH SDWLHQWVWUHDWHGDWPJNJ
RUKLJKHUZLWKQRRURQO\PLOGVLG HHIIHFWVVXSSRUWLQJWKH PJNJGRVHDVWKH+)'DQG
UHFRPPHQGHGIRUIXUWKHUGHYHORSPHQW
7KHSKDUPDFRNLQHWLFVZDVVWXGL HGDWVHOHFWHGWLPHSRLQWVG XULQJWKHWUHDWPHQWDQGWKHGDWD


VKRZHGWKDWQRDFFXPXODWLRQRI$ 35ZDVREVHUYHGDIWHUIRXU GDLO\GRVHVRUDIWHUF\FOHV
3ODVPDFOHDUDQFHDQGYROXPHRIGL VWULEXWLRQZHUHFRPSDUDEOHEHW ZHHQ'D\DQG'D\
VXJJHVWLQJDWLPHLQGHSHQGHQWNLQHWLFV7KH3.SDUDPHWHUVREWDL QHGLQWKHSUHVHQWVWXG\ZHUH
DOVRLQOLQHZLWKWKHSUHYLRXVVLQJOHGRVHVWXG\PJNJ KLQIXVLRQDQGOLQHDUNLQHWLFV
FRXOGEHFRQFOXGHGIRU$35XS WRPJNJ6HYHUDOSDWLHQW VWROHUDWHGWKHPLGGRVH
PJNJWUHDWPHQWZKHUHWKH&PD[ZDVLQWKHUDQJHRIÂ—JP/ ZLWKDQH[SRVXUHXSWR
Â—J
KP/ $8&K ZKHUHDV RQH SD WLHQW ZLWKGUHZ KDYLQJ WKH KLJ KHVW H[SRVXUH 
Â—J
KP/LQWKHZKROHVWXG\7KHUHVXOWVRIWKHH[WHQVLRQVWXG\ RI$35LQSDWLHQWVZLWK
$0/DQG&//VXJJHVWWKDWWKHGRVHUHJLPHQZLWK+)'RIPJN JJLYHQDVDKRXUEL
SKDVLFLQIXVLRQZDVVXLWDEOHDQG WKDW$35ZDVZHOOWROHUDWH GZLWKOLPLWHGQXPEHURI$(V
UHSRUWHG7KHSKDUPDFRNLQHWLFGDWDVXJJHVWHGWLPHLQGHSHQGHQWD QGGRVHLQGHSHQGHQWNLQHWLFV
,QWKHSDWLHQWVSODVPDFRQFHQ WUDWLRQVFRQVLVWHQWO\DERYHWKRVH DVVRFLDWHGZLWKHIIHFWVLQERWKH[
YLYRDQGLQYLYRSUHFOLQLFDOPRGH OVKDYHEHHQDFKLHYHG)RXU SDWLHQWVVKRZHGVLJQVRIUHVSRQVH
DQGRIWKHPZHUHUHVSRQGHUVDFF RUGLQJWRWKHGHILQLWLRQLQWK HSURWRFRO$UHVSRQVHZDV
REVHUYHGLQRIWKHSDWLHQWVFDUU\LQJPXWDQW 737KHHIIHFWRI$35RQWXPRUEXUGHQ
DQGDSRSWRVLVPDUNHUVLQGLFDWHVEH QHILFLDOHIIHFWV*LYHQWKH FULWLFDOXQPHWQHHGIRUWUHDWPHQWRI
73PXWDQW0'6DQG$0/SDWLHQWVZ HSURSRVHWKLVSKDVH,E,,VWXG\ 

$35LQDGYDQFHGRYDULDQFDQFHU

$SDUWVWXG\KDVEHHQGHVLJQH G$35LQZRPHQZLWKDGYDQF HGKLJKJUDGHVHURXVRYDULDQ
FDQFHU+*6&2JLYHQ$35LQF RPELQDWLRQZLWKFDUERSODWLQDQ GSHJ\ODWHGOLSRVRPDO
GR[RUXELFLQ3/'7KLVLVEDVH GRQWKHIDFWWKDW!RI+*62& DUH73PXWDQWDQG LQYLWUR
DQGLQYLYRGDWDVXJJHVWLQJV\QHUJLV PZLWKSODWLQXPDJHQWV7KH$353KDVH,ESRUWLRQLV
QHDUO\FRPSOHWHGLQWKH(XURS HDQ8QLRQDQGWKH UHFRPPHQGHG3KDV H,,GRVHRIPJNJ
FRUUHVSRQGLQJWRPJNJOHDQERG \PDVV/%0KDVEHHQFRQI LUPHGEDVHGXSRQ
DVVHVVPHQWRIFXPXOD WLYHVDIHW\GDWDIURPWKH3KDVH,E&XUUHQW O\DGGLWLRQDOSDWLHQWVDUHEHLQJ
HQUROOHGLQ3KDVH,EH[SDQVLRQFRKRU WWRFROOHFWDGGLWLRQDOVDI HW\DQGFDUGLDF47FDQG3.GDWDDW
WKH3KDVH,,GRVHPJNJ/%0 WKHWDUJHWLVWRKDYHPDWFKH G(&*DQG3.GDWDIURP
SDWLHQWVDWWKH3KDVH ,,GRVH7KH$35 3KDVH,,SRUWLRQZL OORSHQWRDFFUXDOLQWKH(8DIWHU
UHJXODWRU\FOHDUDQFHDQGLQWKH86SHQGLQJ,1'DFWLYDWLRQ$ VX[COMPANY_003]U\RIWKHDGYHUVHHYHQWV
VHHQLQWKLVSURWRFRO DUHGHWDLOHGEHORZ



 











 

















 



 

















 
 
 



 





















 








































































 











 















 






 








 











 















 





















 

 


















678'<(1'32,176
3ULPDU\
3KDVHE'/7VRFFXUULQJLQWKH ILUVWF\FOHVZHHNVDVGH ILQHGEHORZJUDGHG
DFFRUGLQJWRWKH1DWLRQDO&DQFHU ,QVWLWXWH&RPPRQ7HUPLQRORJ\& ULWHULDIRU$GYHUVH(YHQWV
1&,&7&$(9HUVLRQ
3KDVH&5UDWHE\,:* FULWHULDDSSHQGL[%
6HFRQGDU\ 
'XUDWLRQRIUHVSRQVHGHILQHGDVWK HWLPHEHWZHHQDFKLHYLQJUHVS RQVHDQGSURJUHVVLRQRI


GLVHDVH
26DWPRQWKV 
3URSRUWLRQRIVXEMHFWVDFKLHYLQJKH PDWRORJLFDOLPSURYHPHQW+, SDUWLDOUHVSRQVH
35FRPSOHWHUHVSRQVH&5DQG RUPDUURZ&5P&5E\WKH,:* FULWHULDVHH
DSSHQGL[% 
3URSRUWLRQRIVXEMHFWVZKRREWDLQDU HVSRQVHDVGHILQHGE\,:* FULWHULDZLWKD
EDVHOLQH739$)Â•YHUVXV
3URSRUWLRQRIVXEMHFWVZKRDFK LHYHÂ•UHGXFWLRQLQ 739$)
3URJUHVVLRQIUHHVXUYLYDO3)6 DQG26LQFORQDOUHVSRQGHUVÂ• UHGXFWLRQLQ 73
9$)YHUVXVQRQUHVSRQGHUV 
7RGHWHUPLQHH[SUHVVLRQRIJHQH VUHODWHGWRSPHGLDWHGVLJQDO WUDQVGXFWLRQEHIRUHDQG
DIWHU$35WUHDWPHQW
7RGHWHUPLQH526SURGX FWLRQEHIRUHDQGDIWHU $35WUHDWPHQW
$0/WUDQVIRUPDWLRQDFFRUGLQJWR: RUOG+HDOWK2UJDQL]DWLRQ:+2 FULWHULD
26
/)6
'HWHUPLQHUHFXUUHQWJHQHPXWDWLRQVLQ $6;/%&25%5$)&$/5&%/&(%3$
&6)5'107$(79(=+*$7 $*1$6,'+,'+-$..,7 .5$603/1)
13015$63'*)5$3'*)5%3+)37315$'581;6(7%3 6)%
60&$60&656)67$*67$767 $7E7(7738$):7 DQG=565DW
VWXG\HQWU\DQGVHULDOO\WKURXJ KRXWWUHDWPHQWWRDVVHVVFKDQJHV LQVRPDWLFPXWDWLRQODQGVFDSH


3$7,(176(/(&7,21
(OLJLELOLW\FULWHULD
,QFOXVLRQ&ULWHULD
3DWLHQWKDVVLJQHGWKH ,QIRUPHG&RQVHQW,&)DQGLVDEOHWRFR PSO\ZLWKSURWRFRO
UHTXLUHPHQWV
3DWLHQWKDVDGHTXDWHR UJDQIXQFWLRQDVGHILQHGE\WKHIROORZLQJ ODERUDWRU\YDOXHV 
D6HUXPFUHDWLQLQHÂ” [XSSHUOLPLWRIQRUPDO8/1 
E7RWDOVHUXPELOLUXELQ[8/1RUWRWDOELOLUXELQÂ” [8/1ZLWKGLUHFWELOLUXELQ
ZLWKLQQRUPDOUDQJHLQSDWLHQW VZLWKZHOOGRFXPHQWHG*L OEHUWÂ¶V6\QGURPHRU


KHPRO\VLVRUZKRUHTXLUHGUHJXODUEORRGWUDQVIXVLRQV
F$ODQLQHDPLQRWUDQVIHUDVH$/7 DQGDVSDUWDWHDPLQRWUDQVIHUDVH $67[8/1
$JHÂ•\HDUVDWWKHWLPHRIVLJQLQJWKHLQIRUPHGFRQVHQWIRUP 
'RFXPHQWHGGLDJQRVLVRIP\HORG\V SODVWLFV\QGURPH0'60'6P \HORSUROLIHUDWLYH
QHRSODVP031FKURQLFP\HORPRQR F\WLFOHXNHPLD&00/E\:+2F ULWHULDRU$0/
ZLWKP\HOREODVWVUHIUDFWRU \DQHPLDZLWKH[FHVVEODVWVL QWUDQVIRUPDWLRQ5$(%
7E\)UHQFK$PHULFDQ%ULWLVK)$%FULWHULD
'RFXPHQWDWLRQRID 73JHQHPXWDWLRQE\1*6EDVHGRQFHQ WUDORUORFDOHYDOXDWLRQ
5HYLVHG,QWHUQDWLRQDO3URJQRVWLF6FRULQJ6\VWHP,3665FULWHU LDIRU,QWHUPHGLDWH+LJK
ULVNRU9HU\+LJKULVN
$Q(DVWHUQ&RRSHUDWLYH2QFRORJ\* URXS(&2*SHUIRUPDQFHVWDWXV VFRUHRIRULV
UHTXLUHG
,IRIFKLOGEHDULQJSRWHQWLDOQH JDWLYHSUHWUHDWPHQWXULQHRUV HUXPSUHJQDQF\WHVW
,IRIFKLOGEHDULQJSRWHQWLDO PDOHVDQGIHPDOHVZLOOLQJWRXV HDQHIIHFWLYHIRUPRI
FRQWUDFHSWLRQVXFKDVODWH[F RQGRPKRUPRQDOELUWKFRQWUROLQW UDXWHULQHGHYLFHRUGRXEOH
EDUULHUPHWKRGGXULQJFKHPRWKHUDS\W UHDWPHQWDQGIRUDWOHDVWV L[PRQWKVWKHUHDIWHU

([FOXVLRQ&ULWHULD
3DWLHQWKDVDNQRZQKLVWRU\RI+,9 RUDFWLYHKHSDWLWLV%RUDFW LYHKHSDWLWLV&LQIHFWLRQ
WHVWLQJQRWPDQGDWRU\
3DWLHQWKDVDQ\RIWKHIROORZLQJ FDUGLDFDEQRUPDOLWLHVDVGHWH UPLQHGE\WUHDWLQJ0'
D6\PSWRPDWLFFRQJHVWLYHKHDUWIDLOXUH
E0\RFDUGLDOLQIDUFWLRQÂ”P RQWKVSULRUWRHQUROOPHQW
F8QVWDEOHDQJLQDSHFWRULV
G6HULRXVXQFRQWUROOHGFDUGLDFDU[LOCATION_006]\WKPLD
H47FÂ•PVHF
&RQFRPLWDQWPDOLJQDQFLHVRUSUHYLRXVPDOLJQDQFLHVZLWKOHVVWKD QD\HDUGLVHDVHIUHH
LQWHUYDODWWKHWLPHRIVLJQLQJFRQVHQW3DWLHQWVZLWKDGHTXDWH O\UHVHFWHGEDVDORUVTXDPRXV
FHOOFDUFLQRPDRIWKHVNLQRUD GHTXDWHO\UHVHFWHGFDUFLQRPDLQ VLWXHJFHUYL[PD\HQUROO
LUUHVSHFWLYHRIWKHWLPHRIGLDJQRVLV
3ULRUH[SRVXUHWRD]DFLWLGLQHG HFLWDELQHRULQY HVWLJDWLRQDOK\ SRPHWK\ODWLQJDJHQW
8VHRIF\WRWR[LFFKHPRWKHUDSHX WLFDJHQWVRUH[SHULPHQWDODJHQW VDJHQWVWKDWDUHQRW


FRPPHUFLDOO\DYDLODEOHIRUWKH WUHDWPHQWRI0'60'6031&00/ RU$0/ZLWKLQ
GD\VRIWKHILUVWGD\RIVWXG\GUXJWUHDWPHQW
1RFRQFXUUHQWXVHRIHU\WKURLGVWLPXODWLQJDJHQWV*&6)*0& 6)LVDOORZHGGXULQJ
VWXG\H[FHSWLQFDVHVRIIHEULOH QHXWURSHQLDZKHUH*&6)FDQEH XVHGIRUVKRUWWHUP
*URZWKIDFWRUVPXVWEHVWRSSHGGD\VSULRUWRVWXG\
3DWLHQWVZLWKKLVWRU\RIDOORJHQH LFVWHPFHOOWUDQVSODQWDWLRQ
3UHJQDQWZRPHQDUHH[FOXGHGIUR PWKLVVWXG\EHFDXVH$35KDV QRWEHHQVWXGLHGLQ
SUHJQDQWVXEMHFWV%HFDXVHWKH UHLVDQXQNQRZQEXWSRWHQWLDOUL VNIRUDGYHUVHHYHQWVLQ
QXUVLQJLQIDQWVVHFRQGDU\WRWUHD WPHQWRIWKHPRWKHUZLWK$35 EUHDVWIHHGLQJVKRXOG
EHGLVFRQWLQXHGLIWKHPRWK HULVWUHDWHGZLWK$35

,QFOXVLRQRI:RPHQDQG0LQRULWLHV
%RWKPHQDQGZRPHQDQGPHPEHUV RIDOOUDFHVDQGHWKQLFJURXSVD UHHOLJLEOHIRUWKLVWULDO

678'<'(6,*1
7KLVVWXG\ZLOOEHDPXOWLLQ VWLWXWLRQRSHQODEH OSKDVH,E,, FOLQLFDOWULDOFRQGXFWHGLQSDUWVD
3KDVHESDUWIROORZHGE\D6LP RQÂ¶VWZRVWDJH3KDVHGHVLJQ7 KHVWXG\ZLOODVVHVVWKHVDIHW\
DQGHIILFDF\RI$35LQFRPEL QDWLRQZLWKD]DFLWLGLQHIRUWKH WUHDWPHQWRI 73PXWDQW
P\HORLGQHRSODVPV$OOSDWLHQWV ZLOOKDYHSUHVFUHHQLQJ1*6RQ SHULSKHUDOEORRG3%RUERQH
PDUURZ%0VDPSOHVWRGHWHUPLQH 73PXWDWLRQDOVWDWXV DQGWKHUHIRUHHOLJLELOLW\WRSDUWLFLSDWH
LQWKLVVWXG\$3%VDPSOHZLOO EHREWDLQHGSULRUWRWUHDWPHQW IRU1*6E\WKHFHQWUDOODERUDWRU\
WRHYDOXDWHEDVHOLQH 739$)DQGIRUVHULDODQDO\VLV

75($70(173/$1

D$35DGPLQLVWUDWLRQ
7UHDWPHQWZLOOEHDG PLQLVWHUHGRQDQRXWSDWLH QWEDVLV5HSRUWH GDGYHUVHHYHQWVDQGSRWHQWLDO
ULVNVDUHGHVFULEHGLQ6HFWL RQ$SSURSULDWHGRVHPRGLILFDWL RQVIRU$35DUHGHVFULEHGLQ
6HFWLRQ1RLQYHVWLJDWLRQDORUF RPPHUFLDODJHQWVRUWKHUDSL HVRWKHUWKDQWKRVHGHVFULEHG
EHORZPD\EHDGPLQLVWHUHGZLWKW KHLQWHQWWRWUHDWWKHSDWLHQW
 V0'6RU0'6031$35
ZLOOEHVXSSOLHGE\$SUHD



ZLOOEHIROORZHGIRU DWOHDVWZHHNVOHDGLQSKDVHF\FOH EHIRUHWKHVDIHW\RIHDFKFRKRUW
FDQEHIXOO\DVVHVVHGDQGGHFLVL RQVPDGHIRUGRVHHVFDODWLRQLQ WKHQH[WFRKRUW7KH07'LV
GHILQHGDVWKHGRVHOH YHOEHORZZKLFK'/7L VPDQLIHVWHGLQÂ• RIWKHSDWLHQWVRU DWGRVHOHYHO
LI'/7LVPDQLIHVWHGLQ RIWKHSDWLHQW V3KDVHESDWLHQ WVQ WRDSSU R[LPDWHO\
ZLOOUHFHLYH$35LQFRPELQD WLRQZLWKD]DFLWLGLQH&RKRUWVR IDWOHDVWHYDOXDEOHSDWLHQWV
ZLOOEHHQUROOHGXVLQJDPRGLIL HGGHVLJQ,IQR'/7LVREVH UYHGLQDFRKRUWWKHVXEVHTXHQW
SDWLHQWJURXSZLOOEHH QUROOHGDWWKHQH[W SODQQHGGRVHOHYHO ,ID'/7LVREVHUYHGLQRI
SDWLHQWVLQDFRKRUWDWDQ\GRV HOHYHOWKHQXSWRDGGLWLRQDO SDWLHQWVZLOOEHHQU ROOHGDWWKDWGRVH
OHYHO,IRQO\'/7RFFXUVLQW KHSDWLHQWVWUHDWHGDWWKDWG RVHOHYHOWKHV XEVHTXHQWSDWLHQW
JURXSZLOOEHHQUROOH GDWWKHQH[WSODQQH GGRVHOHYHO,IRI SDWLHQWVLQDFRKRU WKDYHD'/7
GRVHHVFDODWLRQFHDVHVDQGWKH07' LVWKHSUHYLRXVGRVHOHYHO ,IRQO\SDWLHQWVZHUHWUHDWHGDW
WKH07'DQDGGLWLRQD OSDWLHQWVZLOOEH LQFOXGHGLQWKHFRKRU WDQGLIRQO\RU'/7RFFXULQ
WKHSDWLHQWVWUHDWHGDWWKDWG RVHOHYHOWKH07'ZLOOEHGHIL QHGDQGZHZLOOSURFHHGWR3KDVH

7DEOH'RVH/HYHOVIRU7UHDWPHQW3DUW$35$]DFLWLGLQH
'RVH/HYHO $35
PJNJ/%: $]DFLWLGLQH
PJP

6WDUWLQJ
GRVH 
  
  

3KDVH3DUW6LPRQÂ¶VWZ RVWDJHPLQLPD[GHVLJQ
)ROORZLQJFRPSOHWLRQRIWKH'RV H)LQGLQJ3KDVHZHZLOOFRQGXFW DGRVHH[SDQVLRQZKHUHE\
SDWLHQWVZLOOEHWUHDW HGZLWK$35DGPLQLV WHUHGDWWKH07'Z LWKD]DFLWLGLQHRQDGD\
F\FOHXWLOL]LQJWKHVDPHGRVLQ JVFKHGXOHDVLQ3KDVHEZLWKWK HH[FHSWLRQRIQROHDGLQSKDVH
LHSDWLHQWVZLOOVWDUWDWGD\ RIFRPELQDWLRQWKHUDS\ZLWK $35RQGD\VDQGD]DFLWLGLQH
RQGD\VRUGD\VDQGRIDGD\F\FOHVHH)LJX UH,IGRVHOHYHOLH
PJNJ/%:LVWKH53'ED VHGRQWKHSKDVHESD UWRIWKHWUL DOWKHGRVLQJZLOOEHFKDQJHG
WRDQHTXLYDOHQWIL[HGGRVHUH JLPHQRIPJSDWLHQWLH$35 DGPLQLVWUDWLRQLQ
FRQVHFXWLYHVWHSVDVDORDGLQJ GRVHPJIRUILUVWPLQXWH VDQGDPDLQWHQDQFHGRVH


PJIRUKRXUVPLQXWHV, IGRVHUHGXFWLRQVRFFXUGXULQ JWKHSKDVHSDUWRIWKHWULDO
DGPLQLVWUDWLRQRIWKH$ 35ZLOODOVREHJLYHQDVDORDGLQJG RVHRIPLQXWHVDQGD
PDLQWHQDQFHGRVHRIKRXUVD QGPLQXWHVVHHEHORZ

'RVH0RGLILFDWLRQ $35'RVH
3KDVH6WDUWLQJ'RVH
/HYHO'/$35JSDWLHQWGD\
JSDWLHQWIRUILUVWPLQXWHVJSDWLHQWIRUKR XUVPLQXWHV
)LUVWGRVHUHGXFWLRQ
'/$35JSDWLHQWGD\
JSDWLHQWIRUILUVWPLQXWHVJSDWLHQWIRU KRXUVPLQXWHV
6HFRQGGRVH'/
 $35JSDWLHQWGD\
JSDWLHQWIRUILUVWPLQXWHVJSDWLHQWIRUK RXUVPLQXWHV


$6LPRQÂ¶VWZRVWDJHPLQLPD[GH VLJQZLOOEHDSSOLHGDVIROORZV 

6WDJH(QUROODWRWDORIHYD OXDEOHSDWLHQWVDWWKH07'LQ FOXGLQJSDWLHQWVZKRZHUHHQUROOHG
GXULQJWKH3KDVHSDUWRIWKHVWXG\,IOHVVWKDQRISD WLHQWVDFKLHYH&5WKHQWKHVWXG\ZLOO
EHWHUPLQDWHGHDUO\ZLWKWKHF RQFOXVLRQWKDWWKHUHJLPHQGRHVQ RWZDUUDQWIXUWKHULQYHVWLJDWLRQ
,IRUPRUHSDWLHQWVDFKLHYH&5 WKHQHQUROOPHQW ZLOOEHSHUPL WWHGWRFRQWLQXHWR6WDJH

6WDJH(QUROOPRUHHYDOXD EOHSDWLHQWVIRUDWRWDORI ,IOHVVWKDQRISDWLHQWVDFKLHYH
&5WKHQWKHUHLVLQVXIILFLHQW HYLGHQFHWRVXSSRUWFRQWLQXHGVW XG\RIWKLVWUHDWPHQW,IRI
SDWLHQWVDFKLHYH&5WKHQWKHUH LVVXIILFLHQWHYLGHQFHWRVXSSR UWIXUWKHUVWXG\RI$35LQ
FRPELQDWLRQZLWKD]DFLWLGLQH LQ3KDVH8SWRDGGLWLRQDOHY DOXDEOHSDWLHQWVZLOOEHWUHDWHGDW
WKHOHYHORIWKH07'LQWKH3 KDVHSRUWLRQRIWKHWULDO7KHP D[LPXPWRWDODFFUXDOLV
SDWLHQWV'LVHDVHDVVHVVPHQWVZ LOORFFXUIROORZLQJF\FOHVRI WKHUDS\)LJXUH




)RUPRVWVXFKGUXJV
WKHUHDUHDOWHUQDWLYHPHGLFLQH VWKDWFRXOGEHFRQVLGHUHG)RUS URSK\OD[LVIRUQDXVHDYRPLWLQJ
SDORQRVHWURQLVWKHSUHIHUUHGD JHQWRYHURQGDQVHWURQ,IIXQJDO SURSK\OD[LVWUHDWPHQWLV
LQGLFDWHGLVDYXFRQD]RQLXPLVSU HIHUUHG$GGLWLRQDOO\WKHIROO RZLQJPHGLFDWLRQVDUH
FRQWUDLQGLFDWHGZKLOHRQ$35
RDQWLDU[LOCATION_006]\WKPLFVFODVV,$H JTXLQLGLQHK\GURTXLQLGLQHGLVR S\UDPLGH
RDQWLDU[LOCATION_006]\WKPLFVFODVV,,,HJ DPLRGDURQHVRWDOROGRIHWLOLG HLEXWLOLGH
RDQWLSV\FKRWLFVHJSKHQRWKLD]L QHVSLPR]LGHVHUWLQGROHKDOR SHULGROVXOWRSULGH
RWULF\FOLFDQWLGHSUHVVDQWV
RVRPHDQWLPLFURELDOVHJVDTXL QDYLUVSDUIOR[DFLQLQWUDYHQRXV HU\WKURP\FLQ
SHQWDPLGLQHDQWLPDODULDOVSDUWLFXODUO\KDORIDQWULQH
RVRPHDQWLKLVWDPLQHVHJWHUIHQDGLQHDVWHPL]ROHPL]RODVWLQH 
RRWKHUPHGLFLQHVHJFLVDSULGH LQWUDYHQRXVYLQFDPLQHEHSULGL ODQGGLSKHPDQLO

LY%ORRG3URGXFWV
7KHXVHRIEORRGSURGXFWVWRLQFO XGHSDFNHGUHGEORRGFHOOV35 %&VDQGSODWHOHW WUDQVIXVLRQV
DUHSHUPLWWHGDQGWREHJ LYHQDWWKHGLVFUH WLRQRIWKHWUHDWLQJ SK\VLFLDQ5HFRPPHQGHG
JXLGHOLQHVIRUWUDQVIXVLRQL QFOXGHDSODWHOHWWKUHVKROGRI /IRUSODWHOHWWUDQVIXVLRQDQGD
KHPRJORELQWKUHVKROGRIJG/IR U35%&WUDQVIXVLRQRUDVFOLQ LFDOO\GHHPHGE\WKHGLVFUHWLRQ
RIWUHDWLQJSK\VLFLDQ


G3URKLELWHG0HGLFDWLRQV
L2WKHUDQWLFDQFHUWKHUDS\
$QWLFDQFHUWKHUDS\FKHPRWKHUDS \HQGRFULQHELRORJLFRUUDGLDW LRQWKHUDS\DQGVXUJHU\RWKHU
WKDQWKHVWXG\WUHDWPHQWVPXVWQRWEHJLYHQWRSDWLHQWVZKLOHW KHSDWLHQWLVHQUROOHGLQWKH
WUHDWPHQWSRUWLRQRIWKHWULDO,I VXFKDJHQWVDUHUHTXLUHGIRU DSDWLHQWWKHQWKHSDWLHQWPXVWEH
SHUPDQHQWO\GLVFRQWLQXHGIURPWK HWUHDWPHQWSRUWLRQRIWKHVWXG \([FHSWLRQIRUEUHDVWFDQFHU
RUSURVWDWHSDWLHQWVRQDGMXYDQW KRUPRQDOWKHUDS\HJDQDVWU R]ROHWDPR[LIHQRUOHXSUROLGH
ZKRKDYHEHHQGLVHDVHIUHH IRUDWOHDVW\HDU
LL2WKHULQYHVWLJD WLRQDOWKHUDSLHV


2WKHULQYHVWLJDWLRQDOWKHUDSLH VPXVWQRWEHXVHGZKLOHWKHSDWL HQWLVRQWKHVWXG\

'XUDWLRQRI7KHUDS\
6XEMHFWVZLOOEHWUHDWHGIRUD WRWDORIF\FOHV)RUVXEMHFWV ZKRKDYHVWDEOHGLVHDVHRUEHWWHU
WUHDWPHQWPD\FRQWLQXH XQWLORQHRIWKHIROOR ZLQJFULWHULDDSSO LHV
H,QWHUFXUUHQWLOOQHVVWKDWSUHYHQWVIXUWKHUDGPLQLVWUDWLRQRI WUHDWPHQW
I8QDFFHSWDEOHDGYHUVHHYHQWV
J3DWLHQWGHFLGHVWRZLWKGUDZIURPWKHVWXG\RU
K*HQHUDORUVSHFLILFFKDQJHV LQWKHSDWLHQW
VFRQGLWLRQUHQGH UWKHSDWLHQWXQDFFHSWDEOHIRU
IXUWKHUWUHDWPHQWLQWKHMXGJ PHQWRIWKHLQYHVWLJDWRU
H(YLGHQFHRIGLVHDVHSURJUH VVLRQE\WKH,:*FULWHULDQR WDSSOLFDEOH
DWERQHPDUURZHYDOXDWLR QDWGD\RIOHDGLQSKDVH 
6XEMHFWVZKRZLVKQRWWRFRQWLQXHW UHDWPHQWZLOOFR PSOHWHWKHLU HQGRIVWXG\YLVLWXSRQ
FRPSOHWLRQRIF\FOH
'XUDWLRQRI)ROORZ8S
6XEMHFWVZLOOEHIROORZHGDVSH UFDOHQGDURQWUHDWPHQWIRUF\ FOHV$IWHUF\FOHVSDWLHQWVZKR
FRQWLQXHRQWUHDWPHQWZ LOOEHIROORZHGPRQWKO\2IIWUHDWPHQWG DWDRQ$0/WUDQVIRUPDWLRQDQG
RYHUDOOVXUYLYDOZLOOEHXSGDWH GHYHU\PRQWKVRUXQWLOGHDWK ZKLFKHYHURFFXUVILUVW6XEMHFWV
UHPRYHGIURPVWXG\IRUXQDFFHSWD EOHDGYHUVHHYHQWVZLOOEHIROO RZHGXQWLOUHVROXWLRQRU
VWDELOL]DWLRQRIWKHDGYHUVHHYHQW

&ULWHULDIRU5HPRYDOIURP6WXG\
D6XEMHFW&RPSOHWLRQ 
$VXEMHFWZLOOEHFRQVLGHUHGWRKDYH FRPSOHWHGWKHVWXG\LIWKH VXEMHFWPHHWVDWOHDVWRIWKH
IROORZLQJFULWHULD
x7KHVXEMHFWKDVSURJUHVVLYHGLVHDVH
x7KHVXEMHFWGLHGGXULQJWKHVWXG\
x7KHVXEMHFWH[SHULHQFHDWUHDWPH QWUHODWHG$(WKDWOHGWRZLWKG UDZDOIURPWKHVWXG\
x7KHVXEMHFWVWDUWVQHZWUHDWPHQW IRUWKHLUXQGHUO\LQJGLVHDVH 0'6&00/$0/
E6XEMHFW:LWKGUDZDOIURP6WXG\


L$VXEMHFWPD\YROXQWDULO\ZLWKGU DZIURPVWXG\PHGLFDWLRQRUZLW KGUDZFRQVHQWIURPWKHVWXG\
DWDQ\WLPH7KHLQYHVWLJDWRUP D\DOVRDWKLVRUKHUGLVFUHWLR QGLVFRQWLQXHDVXEMHFWIURP
SDUWLFLSDWLQJLQWKHVWXG\DWDQ\WLPH7KHLQYHVWLJDWRUDQGRU GHVLJQDWHGVWDIIZLOOUHFRUGWKH
GDWHDQGWKHUHDVRQIRUVXEMHFWZ LWKGUDZDOIURPWKHVWXG\ 
F6XEMHFW:LWKGUDZDOIURP6WXG\0HGLFDWLRQ
,IWKHVXEMHFWLVSHUPDQHQWO\Z LWKGUDZQIURPWUHDWPHQWZLWKVWX G\PHGLFDWLRQEXWGRHVQRW
ZLWKGUDZFRQVHQWWKHLQYHVWLJDW RUPXVWPDNHHYHU\HIIRUWWRKD YHWKHVXEMHFWFRPSOHWHDOO
ZLWKGUDZDODVVHVVPHQWVDWWKHWLPHRIZLWKGUDZDODQGFRPSOHWH DOOVFKHGXOHGIROORZXSYLVLWV
7UHDWPHQWZLWKVWXG\PHGLFD WLRQPXVWEHGLVFRQWLQXHGLI
x7KHVXEMHFWZLWKGUDZVFRQVHQW
x)XUWKHUSDUWLFLSDWLRQZRXOGEHL QMXULRXVWRWKHVXEMHFWÂ¶VKHDOW KRUZHOOEHLQJLQWKH
LQYHVWLJDWRUÂ¶VPHGLFDOMXGJPHQW
x7KHVWXG\LVWHUPLQDWHG
x7KHVXEMHFWEHFRPHVSUHJQDQW
x(YLGHQFHRIGLVHDVHSURJUHVVL RQDFFRUGLQJWR,:*FULWHULD VHH$SSHQGL[%QRW
DSSOLFDEOHDWERQHPDUURZHYDO XDWLRQDWGD\RIOHDGLQSKDV H
x$VXEMHFWLVVLJQLILFDQWO\QRQFR PSOLDQWZLWKWKH UHTXLUHPHQWV RIWKHSURWRFRO
x$VXEMHFWKDVDQDGYHUVHH[SHUL HQFHWKDWZRXOGLQWKHLQYHVWLJ DWRUÂ¶VMXGJPHQWPDNH
FRQWLQXHGSDUWLFLSD WLRQLQWKHVWXG\DQXQDFFHSWDEOHULVN
G6WXG\VDIHW\UHODWHGVWRSSLQJUXOHV
,QWKHIROORZLQJFRQGLWLRQVWKH VWXG\PD\EHWHPSRUDULO\RUSH UPDQHQWO\VWRSSHGSHQGLQJ
UHYLHZE\WKH6WHHULQJ &RPPLWWHHDQGWKH6SRQVRU
3DWLHQWGHDWKGXHWR$35,IW KHUHLV*UDGHWR[LFLW\G HILQLWHO\RUSUREDEO\DWWULEXWHG
WRVWXG\WUHDWPHQWZLWKLQGD\V RI$35DGPLQLVWUDWLRQRU LIWKHUHDUHVXEVHTXHQW
GHDWKVWKDWDUHGHILQLWHO\RU SUREDEO\UHODWHGWRVWXG\WUHDWPH QW

'26,1*'(/$<602',),&$7,216
'RVHPRGLILFDWLRQDQGGRVHGHOD\
)RUSDWLHQWVZKRGRQRWWROHUDWHWK HSURWRFROVSHFLILHGGRVLQJ VFKHGXOHGRVHDGMXVWPHQWVDUH
SHUPLWWHGLQRUGHUWRD OORZWKHSDWLHQWWRFRQWLQXHWKHVWXG\W UHDWPHQW$OOGRVHPRGLILFDWLRQV
LQWHUUXSWLRQVRUGLVFRQWLQXDWL RQVPXVWEHEDVHGRQWKHZRUVWSU HFHGLQJWR[LFLW\DVJUDGHGE\WKH


1&,&OLQLFDO7R[LFLW\&ULWHUL D1&,&7&$(YHUVLRQ2QFHD GRVHKDVEHHQUHGXFHGGXULQJ
DWUHDWPHQWF\FOHUHHVFDOD WLRQZLOOQRWEHSHUPLWWHGGXULQJD Q\VXEVHTXHQWF\FOHZLOOH[FHSWLRQ
RI&16HYHQWVVHH,IWKH DGPLQLVWUDWLRQRI$35LVL QWHUUXSWHGIRUUHDVRQVRWKHUWKDQ
WR[LFLW\WKHQWUHDWPHQWZLWKWKH UHVSHFWLYHVWXG\GUXJPD\EH UHVXPHGDWWKHVDPHGRVH7KH
VDPHSURYLVLRQDSSOLHV LIWKHSDWLHQWH[SHULHQFHGDQXQDFFHSWDE OHWR[LFLW\QRWVSHFLILFDOO\
GHVFULEHGLQ7DEOHSURY LGHGWKDWWKLVWR[LFLW\UHVROYHGWRÂ” &7&$(JUDGHXQOHVVRWKHUZLVH
VSHFLILHG

7UHDWPHQWRIDGYHUVHHYHQWVRI WKH&16UHODWHGWR$35
,IDSDWLHQWUHSRUWVDQ\FOLQLFDO DGYHUVHHYHQWRIDQ\JUDGHGX ULQJWKHDGPLQLVWUDWLRQSHULRGRI
$35WKDWFRXOGEHFRQVLGHUHGW RRULJLQDWHIURPWKHFHQWUDO QHUYRXVV\VWHPHJGL]]LQHVV
YHUWLJRQDXVHDWKHQWKHIROORZL QJPHGLFDWLRQVPD\EHXVHG7D EOH3URFKORUSHUD]LQHLVQRW
UHTXLUHGWREHWDNHQDWDQ\SRLQW EXWLVSHUGLVFUHWLRQRIWKH WUHDWLQJSK\VLFLDQ



7DEOH$GMXYDQW0HGLFDWLRQVIRUXVHZLWK$35 
,QGLFDWLRQ  6XSSRUWLYH0HDVXUH  
Central Nervous System (CNS) symptoms 
(Treatment and Prevention)  Prochlorperazine 10 mg orally tid as needed  
Start Day -1 prior to APR-246 administration  
Persistent CNS symptoms  Diphenhydramine 50 mg IV  (or similar anti-histamine)  

3URFKORUSHUD]LQHPJRUDOO\ WLGWKUHHWLPHVGDLO\WR FRQWLQXHXQWLOHQGRI'D\
RIWKHF\FOH:KHQXVHGSURSK \ODFWLFDOO\IRUIXWXUHWUH DWPHQWVWDUWWKHGD\SULRUWR
'D\DGPLQLVWUDWLRQRI$35 ,IGXULQJWKHLQIXVLRQW KHSDWLHQWFRQWLQXHVWR
UHPDLQV\PSWRPDWLFLQWUDY HQRXVDGPLQLVWU DWLRQRIGLSKHQK \GUDPLQHPJRU
VLPLODUDQWLKLVWDPLQHVKRXO GEHFRQVLGHUHG,ISURSK\ODF WLFSURFKORUSHUD]LQHUHVXOWVLQ
Â”JUDGH&16WR[LFLW\RQVXEV HTXHQWGRVHVUHHVFDODWLRQ WRSUHYLRXVGRVHOHYHOFDQ
RFFXUZLWKWKHQH[WF\FOHDW WKHGLVFUHWLRQRIWKHVWXG\L QYHVWLJDWRU



7UHDWPHQWLQWHUUXSWLRQDQGW UHDWPHQWGLVFRQWLQXDWLRQ
3DWLHQWVUHTXLULQJDGRVHGHOD\ RI!GD\VPXVWEHSHUPDQHQWO \GLVFRQWLQXHGIURPVWXG\GUXJ
)ROORZLQJF\FOHVRIWKHUDS\I RUUHVSRQGLQJSDWLHQWVLH&5 35+,RUPDUURZ&5WUHDWPHQW
ZLWK$35DQGD]DFLWLG LQHFDQEHGHOD\HGSHUWKHVWXG\LQYHV WLJDWRUIRUXSWRGD\VWR
DOORZIRUFRXQWUHFRYHU\RUDW LQYHVWLJDWRUGLVFUHWLRQSRVWGLV FXVVLRQZLWK0RIILWW3,1RQ
KHPDWRORJLFJUDGHWUHDWPHQWUHO DWHGDGYHUVHHYHQWVZLOOOHDG WRSHUPDQHQWGLVFRQWLQXDWLRQ
LUUHVSHFWLYHRIUHFRYHU\WLPHXQO HVVRWKHUZLVHVSHFLILHG([FH SWLRQVZRXOGLQFOXGH
QDXVHDYRPLWLQJGLDU[LOCATION_006]HDZKLFKFDQEHFRQWUROOHGE\PHGLFDWLRQV DQGRUDV\PSWRPDWLF
HOHFWURO\WHLPEDODQFHVZKLFK FDQEHFRUUHFWHG,QDGGLWLRQLQ PRVWLQVWDQFHVSDWLHQWVWKDW
H[SHULHQFHDSURORQJHGWUHDWPH QWLQWHUUXSWL RQEHFDXVHRIDQDGY HUVHHYHQWDQGRUDJUDGH
DGYHUVHHYHQWZLOOGHFUHDVHWKH GRVHRIVWXG\GUXJDIWHUWKHLU UHFRYHU\VHHVSHFLILFWDEOHVIRU
GRVHDGMXVWPHQWJXLGHOLQHV)XU WKHUPRUHSDWLHQWVUHTXLULQJ! GRVHUHGXFWLRQIRU$35ZLOO
EHSHUPDQHQWO\GLVFRQWLQXHGIURP VWXG\GUXJ3DWLHQWVZKRSHUPD QHQWO\GLVFRQWLQXHDOOVWXG\
GUXJVVKRXOGKDYHIROORZXSZLWK LQGD\VDIWHUGLVFRQWLQXDWLR QRIDOOVWXG\WUHDWPHQWRU
UHVROXWLRQRIWKH$(WRÂ”JUDGH ZKLFKHYHURFFXUVILUVWWKDW LQFOXGHVDOOVWXG\DVVHVVPHQWV
DSSURSULDWHWRPRQLWRUWKHHYHQW


'/7'HILQLWLRQ
3DWLHQWVZLOOEHH YDOXDWHGIRU'/7VGXULQJWKHOHDGLQSKDVHDQ GILUVWF\FOHRIFRPELQDWLRQ
WKHUDS\LHZHHNVIRUSXUSRVH RIGHFLGLQJWKHGRVHIRUQH[ WFRKRUWVHH7DEOHEXW'/7V
ZLOOFRQWLQXHWREHH YDOXDWHGDQGUHSRUWH GWKURXJKDOOF\FOHVR QVWXG\'/7LVGHILQHGDVIROORZV
EDVHGRQWKH&7&$(Y
7UHDWPHQWUHODWHGQRQKHPDWRORJ LFDO&7&$(JUDGHWR[LFLW\W KDWOHDGWRGRVHPRGLILFDWLRQ
RUZLWKGUDZDO
$EVROXWHQHXWURSKLOFRXQW$1& QRWUHFRYHULQJWR!Â—/E\G D\RIDF\FOHLQWKHDEVHQFH
RIDFWLYHOHXNHPLDP\HORG\VSODVLDZLOOEHFRQVLGHUHGD'/7
*UDGHPHWDEROLFHOHFWURO\WHD EQRUPDOLWLHVWKDWDUHQRWFOLQL FDOO\VLJQLILFDQWDQGDUH
DGHTXDWHO\FRQWUROOHGZLWKLQKRXU VDUHQRWWREHFRQVLGHUHG '/7 
*UDGHQDXVHDYRPLWLQJGLDU[LOCATION_006]HD RU&16WR[LFLW\WKDWGRHVQRW UHVROYHZLWKLQGD\VGHVSLWH
WUHDWPHQWLQWHUUXSWLRQDQGPD[ LPXPPHGLFDOWKHUDS\ZLOOEHFRQV LGHUHGD'/7

&ULWHULDIRU$35GRVHP RGLILFDWLRQV3KDVH
)RUSDWLHQWVZKRGRQRWWROHUDWH $35LQLWLDOGRVLQJVFKHGXO HGRVHDGMXVWPHQWLVSHUPLWWHG
LQRUGHUWRDOORZWKHSDWLHQWW RFRQWLQXHRQVWXG\GUXJ,QJHQ HUDOGRVHVVKRXOGQRWEHUHGXFHG


IRUJUDGHWR[LFLWLHVRUJUDGH WR[LFLWLHVZLWKUHVROXWLRQRQ GRVHLQWHUUXSWLRQVHH7DEOHEXW
WUHDWPHQWWRFRQWUROV\PSWRPV VKRXOGEHSURYLGHGD VDSSURSULDWH 7KHVWDUWLQJGRVHOHYHORI
$35ZLOOEHEDVHGRQWKHUHFR PPHQGHGSKDVHGRVH53'XS RQFRPSOHWLRQRIWKHSKDVH
FRPSRQHQWRIWKHWULDOVHH7D EOH,IGRVHOHYHOLH PJNJ/%:LVWKH53'EDVHG
RQWKHSKDVHESDUWRIWKH WULDOWKHGRVLQJZLOOEHFKDQJHGW RDQHTXLYDOHQWI L[HGGRVHUHJLPHQ
RIPJSDWLHQW)RUHDFKSDWLH QWDPD[LPXPRIGRVHUHGXF WLRQVRI$35DVRXWOLQHG
LQ7DEOHZLOOEHDOOR ZHG3DWLHQWVUHTXLUL QJDQDGGLWLRQDOG RVHUHGXFWLRQZLOO EHGLVFRQWLQXHG
IURPWUHDWPHQWZLWK$35 3DWLHQWVZKRVH WUHDWPHQWLVLQWHUU XSWHGRUSHUPDQHQWO\
GLVFRQWLQXHGGXHWRDQD GYHUVHHYHQWRUFOLQLFDOO\VLJQLILFDQW ODERUDWRU\YDOXHPXVWEHIROORZHG
XSZLWKLQGD\VRUUHVROXWLRQRIWKH$(WRÂ”JUDGHZKLFKH YHURFFXUVILUVWWKDWLQFOXGHVDOO
VWXG\DVVHVVPHQWVDSSURSULD WHWRPRQLWRUWKHHYHQW

7DEOH'RVHUHGXFWLRQVWHSV IRU$353KDVHRQO\ 
$35GRVHOHYHOVDQGGRVHUHGXFWLRQ

6WDUWLQJGRVHOHYHO 53'GD\VRIHDFKF\FOH
'RVHOHYHOÂ± 53'PJIL[HGGRVHGD\VRIHDFK
F\FOH


'RVHOHYHOÂ± 53'PJIL[HGGRVHGD\VRIHDFK
F\FOH



'RVHUHGXFWLRQVKRXOGEHEDVHGRQWKHZRUVWSUHFHGLQJWR[LFLW\ 


 ,IDGRVHUHGXFWLRQEHORZGRVHOHYHOÂ±LVUHTXLUHGWKHS DWLHQWVKRXOGEHSHUPDQHQWO\GLVFRQWLQXHGIURP$35

*XLGHOLQHVIRUGRVHPRGLILFDWL RQDQGGRVHLQWHUUXSWLRQIRUWR[L FLWLHVVXVSHFWHGWREHUHODWHGWR
$35DUHGHVFULEHGLQ7DEOH

7DEOH$35Â±UHFRPPHQGHGGRVH PRGLILFDWLRQVDQGFULWHULDI RUWUHDWPHQW
LQWHUUXSWLRQDQGUHLQLWLDWLRQZLWKWUHDWPHQWUHODWHGDGYHUVHH YHQWV
7KHVHFKDQJHVPXVWEHUHFRUGH GRQWKH'RVDJH$GPLQLVWUDWLRQ5HF RUG&5)
:RUVWWR[LFLW\&7&$(*UDGH

 'RVH0RGLILFDWLRQVIRU$35 
+(0$72/2*,&$/RQO\DSSOLFDEOHI RUSDWLHQWVZLWKQRUPDOEDVHOLQ HDEVROXWHQHXWURSKLOFRXQW$1&
DQGSODWHOHWV 
1HXWURSHQLD$1& 
6HYHUH)HEULOHQHXWURSHQLD 2P LWGRVHXQWLOUHVROYHGWKHQ ÃˆGRVHOHYHO


:RUVWWR[LFLW\&7&$(*UDGH

 'RVH0RGLILFDWLRQVIRU$35 
$1&[/WHPSHUDWXUHRI
Â•Âƒ&DQG,&8DGPLVVLRQ
7KURPERF\WRSHQLD 
*UDGH3/7[/$1'PDMRU
EOHHGLQJHYHQW3HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35
5(1$/
6HUXPFUHDWLQLQH 
*UDGH[8/1 0DLQWDLQGRVHOHYHO
*UDGHÂ±[8/1 2PLWGRVHXQWLOUHVROYHGWRÂ”JUDGHW KHQ
,IUHVROYHGLQÂ”GD\VWKHQPDLQWDLQGRVHOHYHO
,IUHVROYHGLQ!GD\VWKHQ ÃˆGRVHOHYHO
*UDGH!Â±[8/1 ,IUHVROYHGLQÂ”GD\VWKHQ ÃˆGRVHOHYHO
,IUHVROYHGLQ!GD\VGLVFRQWLQXHSDWLHQWIURP$35
*UDGH![8/1 3HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35 
+(3$7,& 
%LOLUXELQ

IRUSDWLHQWVZLWK*LOEHUW6\QGURPHWKHVHGRVHPRGLILFDWLRQV DSSO\WRFKDQJHVLQGLUHFWELOLUXELQRQO\
ZLOOEHIUDFWLRQDWHGLIHOHYDWHG
*UDGH!8/1[8/1 0DLQWDLQGRVHOHYHOZLWK/)7V
PRQL WRUHGDVSHUSURWRFRO
*UDGH![8/1ZLWK$/7RU
$67Â”[8/12PLWGRVHXQWLOUHVROYHGWRÂ”*UDGHWKHQ
,IUHVROYHGLQÂ”GD\VWKHQPDLQWDLQGRVHOHYHO,IUHVROYHGLQ!GD\VWKHQ ÃˆGRVHOHYHO
*UDGH![8/1ZLWK$/7RU
$67Â”[8/12PLWGRVHXQWLOUHVROYHGWRÂ”*UDGHWKHQ
,IUHVROYHGLQÂ”GD\V ÃˆGRVHOHYHO
,IUHVROYHGLQ !GD\VGLVFRQWLQXHSDWLHQWIURP$35
*UDGH![8/1 3HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35 
$67RU$/7 
*UDGH!8/1Â±[8/1 0DLQWDLQGRVHOHYHOZLWK/)7V
PRQL WRUHGSHUSURWRFRO
*UDGH![8/1ZLWKRXWWRWDO
ELOLUXELQHOHYDWLRQWR![8/12PLWGRVHXQWLOUHVROYHGWRÂ”*UDGHWKHQ
,IUHVROYHGLQÂ”GD\VWKHQPDLQWDLQGRVHOHYHO
,IUHVROYHGLQ!GD\VWKHQ ÃˆGRVHOHYHO
*UDGH![8/1ZLWKRXWWRWDO
ELOLUXELQHOHYDWLRQWR![8/12PLWGRVHXQWLOUHVROYHGWRÂ”*UDGHWKHQ
,IUHVROYHGLQÂ”GD\VWKHQPDLQWDLQGRVHOHYHO,IUHVROYHGLQ!GD\VWKHQ ÃˆGRVHOHYHO


:RUVWWR[LFLW\&7&$(*UDGH

 'RVH0RGLILFDWLRQVIRU$35 
*UDGH![8/1ZLWKRXWELOLUXELQ
HOHYDWLRQWR![8/13HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35

/)7VLQFOXGHDOEXPLQ$/7$67WRWDOELOLUXELQIUDFWLRQDWHG LIWRWDOELOLUXELQ![8/1DONDOLQH
SKRVSKDWDVH
&16Â±GL]]LQHVVG\VNLQHVLDDQGDWD[LD 
*UDGH 0DLQWDLQGRVHOHYHO
*UDGH ,IUHVROYHGZLWKPHGLFDOWKHUDS\HJ SURFKORUSHUD]LQHRUDQWLKLVWDPLQHV
FRQWLQXHVDPHGRVHOHYHO,IQRWUHVROYHGGHVSLWHWUHDWPHQWLQWHUUXSWLRQDQGPD[LPDOPHGL FDO
WKHUDS\
VWRSLQIXVLRQDQG ÃˆGRVHOHYHOIRUVXEVHTXHQWGRVH
*UDGH ,IUHVROYHGZLWKPHGLFDOWKHUDS\HJ SURFKORUSHUD]LQHRUDQWLKLVWDPLQHV
FRQWLQXHVDPHGRVHOHYHO,IQRWUHVROYHGGHVSLWHWUHDWPHQWLQWHUUXSWLRQDQGPD[LPDOPHGL FDO
WKHUDS\
VWRSLQIXVLRQDQG ÃˆGRVHOHYHOIRUVXEVHTXHQWGRVH
*UDGH 3HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35
,QIXVLRQ5HODWHG5HDFWLRQ 
*UDGH 0DLQWDLQGRVHOHYHO

*UDGH 0DLQWDLQGRVHOHYHO6\PSWRPDWLFPDQDJHPHQWHJDQWLKLVWDPLQ HV
FRUWLFRVWHURLGVQDUFRWLFV,9IOXLGV

*UDGH ,IUHVROYHGLQKRXUVZLWKWUHDWPHQWLQWHUUXSWLRQDQGPHGLFD OWKHUDS\HJ
DQWLKLVWDPLQHVFRUWLFRVWHURLGV QDUFRWLFV,9IOXLGVFRQWLQX HVDPHGRVHOHYHO
DQGUDWH,IQRWUHVROYHGLQKRXUVGHVSLWHWUHDWPHQWLQWHUUXSWLRQDQG PD[LPDOPHGLFDO
WKHUDS\VWRSLQIXVLRQDQG ÃˆGRVHOHYHOIRUVXEVHTXHQWGRVH
*UDGH 3HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35
1DXVHD9RPLWLQJ'LDU[LOCATION_006]HD 
*UDGH 0DLQWDLQGRVHOHYHO
*UDGH ,IUHVROYHGWKHQPDLQWDLQGRVHOHYHO
,IQRWUHVROYHGGHVSLWHP D[LPDOPHGLFDOWKHUDS\
WKHQÃˆGRVHOHYHO
*UDGH ,IUHVROYHGWKHQPDLQWDLQGRVHOHYHO
,IQRWUHVROYHGGHVSLWHP D[LPDOPHGLFDOWKHUDS\
WKHQÃˆGRVHOHYHO
*UDGH 3HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35


:RUVWWR[LFLW\&7&$(*UDGH

 'RVH0RGLILFDWLRQVIRU$35 
47F3URORQJDWLRQ  
*UDGH 0DLQWDLQGRVHOHYHO
*UDGH &RUUHFWHOHFWURO\WHVDQ GGLVFRQWLQXHFRQFRPLWDQWPHGLF DWLRQVWKDW
FDXVH47FSURORQJDWLRQ,IUHVROYHGWKHQPDLQWDLQGRVHOHYHO 
,IQRWUHVROYHGWKHQ ÃˆGRVHOHYHO
*UDGH 2PLWGRVHXQWLOUHVROYHGWRÂ”*UDGH
,IUHVROYHGWKHQ ÃˆGRVHOHYHO
,IQRWUHVROYHGGHVSLWHFRUUHFWLRQRIHOHFWURO\WHVDQGGLVFRQWL QXDWLRQRI
FRQFRPLWDQWPHGLFDWLRQVWKDWFDXVH47FSURORQJDWLRQSHUPDQHQWO \
GLVFRQWLQXHPD[LPDOPHGLFDOWKHUDS\
*UDGH 3HUPDQHQWO\GLVFRQWLQXHSDWLHQWIURP$35


&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(YHUVL RQ
7KHVHFKDQJHVPXVWEHUHFRUGHGR QWKH'RVDJH$GPLQLVWUDWLRQ5HF RUGH&5)

$'9(56((9(1765(3257,1*5(48,5(0(176

$OO6$(VVKRXOGEHUHSRU WHGWRWKHSULQFLSDO LQYHVWLJDWRUDW+ /HH0RIILWW&DQFHU&HQWHUDVZHOO
DVWKHFOLQLFDOUHVHDUFKFRRUGLQDWRULPPHGLDWHO\$OO6$(VPXVW DOVREHUHSRU WHGZLWKLQKRXUV
RIEHLQJNQRZQWR$SUHD 7KHVHWR[LFLWLHVZ LOOEHUHYLHZHGE\W KHSULQFLSDOLQYHVWLJDWRUDQG
DSSURSULDWHPHDVXUHVWDNHQLQWHU PVRIGHOD\LQJRUUHGXFLQJRU RPLWWLQJWKHQH[WF\FOHRI
WKHUDS\$Q\6$(RFFXUULQJIURPWKHWLPHRIDGPLQLVWUDWLRQRIW KHILUVWGRVHRIVWXG\GUXJXQWLO
GD\VDIWHUWKHILQDOGRVHRIVWXG\GUXJPXVWEHSURPSWO\UHS RUWHGWR$SUHDYLDID[RQD
UHGDFWHGFRS\RIWKH2QFRUHGDWD EDVH6$(IRUP$Q\6$(RFFXUULQ JDIWHUWKLVWLPHWKDWLV
WKRXJKWWREHSRVVLEO\UHODWHGW RSULRUWUHDWPHQWZLWKVWXG\GU XJVKRXOGDOVREHUHSRUWHGDQG
UHFRUGHGRQWKH$(ORJ6$(VPX VWEHIROORZHGXQWLOUHVROXWLRQ RUGHHPHGLUUHYHUVLEOH$OO
UHOHYDQWIROORZXSLQI RUPDWLRQPXVWEHSURPSW O\UHSRUWHGDQGUH FRUGHGLQWKH2QFRUHGDWDEDVH

D'HILQLWLRQRIDQ$(
$Q\XQWRZDUGPHGLFDORFFXUUHQFH LQDVXEMHFWRUFOLQLFDOLQYHVW LJDWLRQVXEMHFWWHPSRUDOO\
DVVRFLDWHGZLWKWKHXVHRIDPHG LFLQDOSURGXFWZKHWKHURUQRW FRQVLGHUHGUHODWHGWRWKH
PHGLFLQDOSURGXFW1RWH$Q$(FD QWKHUHIRUHEHDQ\XQIDYRUDEOH DQGXQLQWHQGHGVLJQ
LQFOXGLQJDQDEQRUPDOODERUDWRU \ILQGLQJV\PSWRPRUGLVHDVH QHZRUH[DFHUEDWHG


WHPSRUDOO\DVVRFLDWHGZLWKWKH XVHRIDPHGLFLQDOSURGXFW (YHQWVPHHWLQJWKHGHILQLWLRQRIDQ
$(LQFOXGH
Â‡([DFHUEDWLRQRIDFKURQLFRUL QWHUPLWWHQWSUHH[LVWLQJFRQGLWL RQLQFOXGLQJHLWKHUDQLQFUHDVHLQ
IUHTXHQF\DQGRULQWHQVLW\RIWKHFRQGLWLRQ
Â‡1HZFRQGLWLRQVGHWHFWHGRUGLDJQRV HGDIWHULQYHVWLJDWLRQDOSUR GXFWDGPLQLVWUDWLRQHYHQWKRXJK
LWPD\KDYHEHHQSUHVHQWSULRU WRWKHVWDUWRIWKHVWXG\
Â‡6LJQVV\PSWRPVRUWKHFOLQLFDO VHTXHODHRIDVXVSHFWHGLQWHU DFWLRQ
Â‡6LJQVV\PSWRPVRUWKHFOLQLFDO VHTXHODHRIDVXVSHFWHGRYHUG RVHRIHLWKHUL QYHVWLJDWLRQDO
SURGXFWRUDFRQFRPLWDQWPHGLFD WLRQRYHUGRVHSHUVHZLOOQRWE HUHSRUWHGDVDQ$(6$(
Â³/DFNRIHIILFDF\Â´RUÂ³IDLOXUH RIH[SHFWHGSKDUPDFRORJLFDODFWL RQÂ´SHUVHZLWKLQWKHGXUDWLRQ
RILQLWLDO$35WU HDWPHQWH[SRVXUHRI F\FOHVZLOOQRWEHU HSRUWHGDVDQ$(RU6$(
+RZHYHUWKHVLJQVDQGV\PSWRPV DQGRUFOLQLFDOVHTXHODHUHVXOW LQJIURPODFNRIHIILFDF\ZLOO
EHUHSRUWHGLIWKH\IXOILOOWK HGHILQLWLRQRIDQ$(RU6$(
x6WRSGDWHVIRU$(VFDQEHHLWKHU WKHODVWGDWHWKDWWKH$(RFF XUUHGRUWKHQH[WGDWHZKLFK
UHIOHFWVDFKDQJHLQJUDGHVWDWXV


(YHQWVWKDW GRQRWPHHWWKHGHILQLWLRQRIDQ$(LQFOXGH
Â‡0HGLFDORUVXUJLFDOSURFHGXUH HJHQGRVFRS\DSSHQGHFWRP\ WKHFRQGLWLRQWKDWOHDGVWRWKH
SURFHGXUHLVHLWKHUDQ$(RULI H[LVWLQJSUHVWXG\DEDVHOLQH PHGLFDOKLVWRU\LWHP
Â‡6LWXDWLRQVZKHUHDQXQWRZDUGP HGLFDORFFXUUHQFHGLGQRWRFFXU VRFLDODQGRUFRQYHQLHQFH
DGPLVVLRQWRDKRVSLWDO([DPSOH +RVSLWDODGPLVVLRQIRUVROH SXUSRVHRIUHGEORRGFHOO
WUDQVIXVLRQ
Â‡$QWLFLSDWHGGD\WRGD\IOXFWXDWLRQVRISUHH[LVWLQJGLVHDVHV RUFRQGLWLRQVSUHVHQWRU
GHWHFWHGDWWKHVWDUWRIW KHVWXG\WKDWGRQRWZRUVHQ
Â‡6LJQVV\PSWRPVRI*URU*U H[SHFWHGVLGHHIIHFWVRI$]DF LWLGLQHDVQRWHGLQYLVLWQRWHVE\
WUHDWLQJ0'DQGRUGH VLJQDWHGVWDII7KLVLQFOXGHVIRUH[DPSO HEXWQRWOLPLWHGWR*U
1DXVHDFRQVWLSDWLRQLQMHFWLRQV LWHUHDFWLRQVGHFUHDVHGQHXWU RSKLOFRXQWGHFUHDVHGSODWHOHW
FRXQW0XVWEHORFDWHGLQVRXUFH GRFXPHQWWKDWLWHPVDUHVSHFL ILFDOO\DWWULEXWDEOHWR
$]DFLWLGLQH


x6LJQVV\PSWRPVRI*URU*UH [SHFWHGVLGHHIIHFWVRIUHGE ORRGFHOODQGRUSODWHOHW
WUDQVIXVLRQQHHGV7KLVLQFO XGHVIRUH[DPSOHEXWQRWOLPLWHG WR*UGL]]LQHVV
KHDGDFKHK\SRWHQVLRQK\SHUWHQVLRQG\VSQHDPXVFOHZHDNQHVV DWD[LDIDOOSHWHFKLDH
EUXLVLQJ0XVWEHORFDWHGLQVRXU FHGRFXPHQWWKDWLWHPVDUHVS HFLILFDOO\DWWULEXWDEOHWRWKH
QHHGIRUUHGEORRGFHOOWUDQVIXV LRQDQGRUSODWHOHWWUDQVIXVLRQ 
x,WHPVZKLFKDUHWUDQVLHQWH[DP SOHVHDVRQDODOOHUJLHVMRLQW SDLQGXULQJWKXQGHUVWRUPVZLOO
EHOLVWHGDVEDVHOLQH PHGLFDOKLVWRU\LWHPVDQGDUHQRWFRQVLGH UHGQHZ$(VLIRQO\RFFXUULQJ
GXULQJFHUWDLQWLPHVRI\HDURUZ LWKFHUWDLQHYHQWVLIRQJRLQJ FKURQLFDOO\DQGGRQRWLQFUHDVH
LQJUDGHDQGDUHQRWDWWULEXW DEOHWRVWXG\PHGLFDWLRQ
E6HULRXV$GYHUVH(YHQW6$('HILQLWLRQ 
$VHULRXVDGYHUVHHYHQWLVRQHW KDWDWDQ\GRVHLQFOXGLQJRYHU GRVH
Â‡5HVXOWVLQGHDWK
Â‡,VOLIHWKUHDWHQLQJ
Â‡5HTXLUHVLQSDWLHQW KRVSLWDOL]DWLRQRUSURO RQJDWLRQRIH[LVWLQ JKRVSLWDOL]DWLRQ
Â‡5HVXOWVLQSHUVLVWHQWRUVLJQLIL FDQWGLVDELOLW\RULQFDSDFLW\ 
Â‡,VDFRQJHQLWDODQRPDO\RUELUWKGHIHFW
Â‡,VDQLPSRUWDQWPHGLFDOHYHQW
Â‡6XVSHFWHGSRVLWLYHSUHJQDQF\
127(7KHWHUPÂ³OLIHWKUHDWHQLQ JÂ´WKHGHILQLWLRQUHIHUVWRDQH YHQWLQZKLFKWKHVXEMHFWZDVDW
ULVNRIGHDWKDWWKHWLPHRIWKH HYHQW,WGRHVQRWUHIHUWRDQ HYHQWZKLFKK\SRWKHWLFDOO\PLJKW
KDYHFDXVHGGHDWKLILW ZHUHPRUHVHYHUH
x5HTXLUHVKRVSLWDOL]DWLRQRUSU RORQJDWLRQRIH[LVWLQJKRVSLWDOL] DWLRQ127(,QJHQHUDO
KRVSLWDOL]DWLRQVLJQLILHVWKDWWK HVXEMHFWKDVEHHQGHWDLQHGX VXDOO\LQYROYLQJDWOHDVWDQ
RYHUQLJKWVWD\DWWKHKRVSLWDO RUHPHUJHQF\ZDUGIRUREVHUYDWL RQDQGRUWUHDWPHQWWKDWZRXOG
QRWKDYHEHHQDSSURSULDWHLQWKHSK \VLFLDQÂ¶VRIILFHRURXWSDWL HQWVHWWLQJ&RPSOLFDWLRQVWKDW
RFFXUGXULQJKRVSLWDOL]DWLRQDUH $(V,IDFRPSOLFDWLRQSURORQJ VKRVSLWDOL]DWLRQRU IXOILOOVDQ\
RWKHUVHULRXVFULWHULDWKHH YHQWLVVHULRXV:KHQLQGRXEWDV WRZKHWKHUÂ³KRV SLWDOL]DWLRQÂ´
RFFXUUHGRUZDVQHFHVVDU\WKH $(VKRXOGEHFRQVLGHUHGVHULRXV +RVSLWDOL]DWL RQIRUHOHFWLYH
WUHDWPHQWRIDSUHH[LVWLQJF RQGLWLRQWKDWGLGQRWZRUVHQIURP EDVHOLQHLVQRWFRQVLGHUHGDQ
$(
x5HVXOWVLQGLVDELOLW\LQFDSDFLW\


127(7KHWHUPGLVDELOLW\PHDQV DVXEVWDQWLDOGLVUXSWLRQRIDS HUVRQÂ¶VDELOLW\WRFRQGXFW
QRUPDOOLIHIXQFWLRQV7KLVGHIL QLWLRQLVQRWLQWHQGHGWRLQFOX GHH[SHULHQFHVRIUHODWLYHO\
PLQRUPHGLFDOVLJQLILFDQFHVXF KDVXQFRPSOLFDWHGKHDGDFKHQDXV HDYRPLWLQJGLDU[LOCATION_006]HD
LQIOXHQ]DDQGDFFLGHQWDOWUDXPD HJVSUDLQHGDQNOHZKLFKP D\LQWHUIHUHRUSUHYHQW
HYHU\GD\OLIHIXQFWLRQVEXWGRQRW FRQVWLWXWHDVXEVWDQWLDOGLV UXSWLRQ
x$OOWUHDWPHQWUHODWHGJUDGHQRQKH PDWRORJLFODERUDWRU\DEQRUP DOLWLHVDVVHVVHGXVLQJWKH
1DWLRQDO&DQFHU,QVWLWX WH1&,&RPPRQ7HUPLQRORJ\&ULWHULDIRU $GYHUVH(YHQWV&7&$(
Y
0HGLFDORUVFLHQWLILFMXGJPHQWV KRXOGEHH[HUFLVHGLQGHFLGLQJ ZKHWKHUUHSRUWLQJLVDSSURSULDWH
LQRWKHUVLWXDWLRQVVXFKDVLPSRU WDQWPHGLFDOHYHQWVWKDWPD\ QRWEHLPPHGLDWHO\OLIH
WKUHDWHQLQJRUUHVXOWLQGHDWKRUKRVSLWDOL]DWLRQEXWPD\MHRSD UGL]HWKHVXEMHFWRUPD\UHTXLUH
PHGLFDORUVXUJLFDOLQWHUYHQWL RQWRSUHYHQWRQHRIWKHRWKHURX WFRPHVOLVWHGLQWKHDERYH
GHILQLWLRQ7KHVHVKRXO GDOVREHFRQVLGHUHGVHULRXV([DPSOHVR IVXFKHYHQWVDUHLQYDVLYHRU
PDOLJQDQWFDQFHUVLQWHQVLYHWU HDWPHQWLQDQHPHUJHQF\URRPRU DWKRPHIRUDOOHUJLF
EURQFKRVSDVPRUFRQYXOVLRQVWKD WGRQRWUHVXOWLQKRVSLWDOL]DW LRQRUGHYHORSPHQWRIGUXJ
GHSHQGHQF\RUGUXJDEXVH
F5HODWLRQVKLSWR,QYHV WLJDWLRQDO3URGXFW
,WLVDUHJXODWRU\UHTXLUHPHQWI RULQYHVWLJDWRUVWRDVVHVVUHOD WLRQVKLSWRLQYHVWLJDWLRQDO
SURGXFWEDVHGRQLQIRUPD WLRQDYDLODEOH7KH DVVHVVPHQWVKRXOGE HUHYLHZHGRQUHFHLSWRIDQ\
QHZLQIRUPDWLRQDQGDPHQGHGLI QHFHVVDU\Â³$UHDVRQDEOHSRVVLEL OLW\Â´LVPHDQWWRFRQYH\WKDW
WKHUHDUHIDFWVHYLGHQFHRUDUJXPHQWVWRVXJJHVWDFDXVDOUHODW LRQVKLS)DFWVHYLGHQFHRU
DUJXPHQWVWKDWPD\VXSSRUWÂ³DU HDVRQDEOHSRVVLELOLW\Â´LQFOXGH HJDWHPSRUDOUHODWLRQVKLSD
SKDUPDFRORJLFDOO\SUHGLFWHGHYH QWRUSRVLWLYHGHFKDOOHQJHRUU HFKDOOHQJH&RQIRXQGLQJIDFWRUV
VXFKDVFRQFRPLWDQWP HGLFDWLRQDFRQFXUUHQW LOOQHVVRUUHOHYD QWPHGLFDOKLVWRU\VKRXOGDOVREH
FRQVLGHUHG
G/DERUDWRU\DQG2WKHU6DIHW\$VVHVVPHQW$EQRUPDOLWLHV5HSRUWHGD V$(VDQG6$(V
$Q\DEQRUPDOODERUDWRU\WHVWUHVX OWVKHPDWRORJ\ FOLQLFDOFKHP LVWU\RUXULQDO\VLVRURWKHU
VDIHW\DVVHVVPHQWVHJ(&*VY LWDOVLJQVPHDVXUHPHQWVLQFO XGLQJWKRVHWKDWZRUVHQIURP
EDVHOLQHVKRXOGEHUHFRUGHGDVSH UWKH1&,&7&$(FULWHULD +RZHYHUWKHVHODERUDWRU\
UHVXOWVDUHWREHUHFRUGHGDV$(V RU6$(VLIGHHPHGFOLQLFDOO\ VLJQLILFDQWLQWKHPHGLFDODQG
VFLHQWLILFMXGJPHQWRI WKHLQYHVWLJDWRURUW UHDWLQJSK\VLFLDQ $Q\FOLQLFDOO\VLJQLILFDQWVDIHW\


DVVHVVPHQWVWKDWDUHDVVRFLDWH GZLWKWKHXQGHUO\LQJGLVHDVHDUH QRWWREHUHSRUWHGDV$(VRU
6$(VH[FHSWIRUILQGLQJVMXGJHGE \WKHLQYHVWLJDWRURUWUHDWLQ JSK\VLFLDQWREHP RUHVHYHUHWKDQ
H[SHFWHGIRUWKHVXEMHFWÂ¶VF RQGLWLRQRUGHDWK'DWDZLOOEHFRO OHFWHGIRUW\SLFDOGLVHDVHUHODWHG
HYHQWVVXFKDVDQHPLDOHXNRSHQLD RUZRUVHQLQJRIWKURPERF\WRSH QLD$OOLQIHFWLRQVH[SHULHQFHG
GXULQJWKHVWXG\DUHWREHUHFRUGHGDV$(VRU6$(V
H'LVHDVH5HODWHG(YHQWVDQGRU'LVHDVH5HODWHG2XWFRPHV1RW4XDO LI\LQJDV6$(V
'XULQJWKHVWXG\SHULRGWKHIROORZLQJFRQGLWLRQVZLOOQRWTXDO LI\DVDQ$(RU6$(SURYLGHG
WKH\DUHQRWFRQVLGHUHGDWWULEXW DEOHWRVWXG\PHGLFDWLRQ
x(YHQWVWKDWRFFXUSULRUWRWKHVWGRVHRI$35
x&DVHVRIGLVHDVHSURJUHVVLRQ
I3UHJQDQF\
$Q\SUHJQDQF\WKDWRFFXUVGXULQJVWXG\SDUWLFLSDWLRQPXVWEHUH SRUWHG7RHQVXUHVXEMHFWVDIHW\
HDFKSUHJQDQF\PXVWEHUHSRUWHGW RWKH)'$ZLWK&&QRWLILFDWLRQ WR$SUHDZLWKLQZHHNVRI
OHDUQLQJRILWVRFFXUUHQFH7KH SUHJQDQF\PXVWEHIROORZHGXSW RGHWHUPLQHRXWFRPHLQFOXGLQJ
SUHPDWXUHWHUPLQDWLRQDQGVWDWX VRIPRWKHUDQGFKLOG3UHJQDQF \FRPSOLFDWLRQVDQGHOHFWLYH
WHUPLQDWLRQVIRUPHGLFDOUHDVRQV PXVWEHUHSRUWHGDVDQ$(RU6 $(6SRQWDQHRXVDERUWLRQVPXVW
EHUHSRUWHGDVDQ6$( $Q\6$(RFFXUULQJLQDVVRFLDWLRQZLWKDSUHJQDQF\EURXJKWWRW KH
LQYHVWLJDWRUÂ¶VDWWHQWLRQDIWHUW KHVXEMHFWKDVFRPSOHWHGWKHVW XG\DQGFRQVLGHUHGE\WKH
LQYHVWLJDWRUDVSRVVLEO\UHODWH GWRWKHLQYHVWLJ DWLRQDOSURGXFW PXVWEHSURPSWO\UHSRUWHGWRWKH
SKDUPDFRYLJLOLDQFHJURXSVDWWKH+/HH0RIILWW&DQFHU&HQWHUD QG$SUHD,QDGGLWLRQWKH
LQYHVWLJDWRUPXVWDWWHPSWWRF ROOHFWSUHJQDQF\LQIRUPDWLRQRQD Q\IHPDOHSDUWQHUVRIPDOHVWXG\
VXEMHFWVZKREHFRPHSUHJQDQWZK LOHWKHVXEMHFWLVHQUROOHGLQW KHVWXG\3UHJQDQF\LQIRUPDWLRQ
PXVWEHUHSRUWHGWRWKH+/HH0RIILWW&DQFHU&HQWHUDVGHVFULE HGDERYH

J3URPSW5HSRUWLQJRI6HULRXV$GY HUVH(YHQWVDQG2WKHU(YHQWVWR $SUHD
7KHLQYHVWLJDWRUPXVWLQIRUP $SUHDRIDQ\6$(ZLWKLQKRXUVR IEHLQJDZDUHRIWKHHYHQW
7KLVPXVWEHGRFXPHQWHGLQ2QF RUHSULQWHGVLJ QHGGDWHGDQGH PDLOHGWR$SUHDYLD7KHUDGH[
DW
6DIHW\'HVN(XURSH#WKHUDGH[FRXN 7KLVIRUPPXVWEHFRPSOHW HGDQGVXSSOLHGWR$SUHDZLWKLQ
KRXUVEXVLQHVVGD\7KHLQLWLDO UHSRUWPXVWEHD VFRPSOHWHDV SRVVLEOHLQFOXGLQJDQDVVHVVPHQW
RIWKHFDXVDOUHODWLRQVKLSEHWZ HHQWKHHYHQWDQGWKHLQYHVWLJDW LRQDOSURGXFWLIDYDLODEOH


,QIRUPDWLRQQRWDYDLODEOHDWWKH WLPHRIWKHLQLWLDOUHSRUWPXV WEHGRFXPHQWHGLQ2QFRUHDVD
IROORZXS6$(DOVRSULQWHGVLJ QHGGDWHGDQGHPDLOHGWR$SUHD YLD7KHUDGH[DW
6DIHW\'HVN(XURSH#WKHUDGH[FRXN ,IWKH6$(LVGHHPHGUHSRUWD EOHWRWKH)'$WKHQD0HG:DWF K
ZLOODOVRQHHGWREHFRPSOHWHGD QGVHQWWR0RIILWW&DQFHU&HQWH UIRUUHYLHZVHH,1'VHFWLRQ
IRUIXUWKHUGHWDLOVDQG)'$VXEPLVVLRQ
$ILQDOUHSRUWWRGRFXPHQWUH VROXWLRQRIWKH6$(LVUHTXLU HG$Q\VHULRXVDGYHUVHHYHQWV
ZKLFKRFFXUGXULQJWKHFOLQLFDO VWXG\RUZLWKLQGD\VRIUHFH LYLQJWKHODVWGRVHRIVWXG\
PHGLFDWLRQZKHWKHURUQRWUHOD WHGWRWKHVWXG\GUXJPXVWEHU HSRUWHGE\WKHLQYHVWLJDWRU,Q
DGGLWLRQDQ\6$(VZKLFKRFFXUDVD UHVXOWRISURWRFROVSHFLILF GLDJQRVWLFSURFHGXUHVRU
LQWHUYHQWLRQVPXVWDOVREHUHSRU WHG6$(VEURXJKWWRWKHDWWHQW LRQRIWKHLQYHVWLJDWRUDWDQ\WLPH
DIWHUFHVVDWLRQRI$35 DQGFRQVLGHUHGE\WKHLQYHVWLJDWRUW REHUHODWHGRUSRVVLEO\UHODWHGWR
$35PXVWEHUHSRUWHGWR$SUHD ZLWKVXEVHTXHQWWRWKH)'$LI DQGZKHQWKH\RFFXU
$GGLWLRQDOO\LQRUGHUWRIXOI LOOLQWHUQDWLRQDOUHSRUWLQJREOLJ DWLRQV6$(VWKDWDUHUHODWHGWRVWXG\
SDUWLFLSDWLRQHJSURFHGXUHVL QYDVLYHWHVWVDQGRUFKDQJH IURPH[LVWLQJWKHUDS\RUDUHUHODWHG
WRDFRQFXUUHQWPHGLFDWLRQZLOOEH FROOHFWHGDQGUHFRUGHGIURP WKHWLPHWKHVXEMHFWFRQVHQWVWR
SDUWLFLSDWHLQWKHVWXG\X QWLOKHVKHLVGLVFKDUJHG

 ,QLWLDO5HSRUWV )ROORZXS,QIRUPDWLRQRQD
3UHYLRXV5HSRUW
7\SHRI(YHQW 7LPH
)UDPH'RFXPHQWV 7LPH)UDPH 'RFXPHQWV
$OO6$(V KRXUV
 Â³6$(Â´GDWD
FROOHFWLRQWRROKRXUV
 8SGDWHGÂ³6$(Â´
GDWDFROOHFWLRQ
WRRO
3UHJQDQF\ :HHNV
 3UHJQDQF\
1RWLILFDWLRQ)RUP:HHNV
 3UHJQDQF\
)ROORZXS)RUP

)URPWKHWLPHSRLQWZKHQWKH6$( RUSUHJQDQF\EHFDPHNQRZQWRU HSRUWHU

K5HJXODWRU\5HSRUWLQJ5 HTXLUHPHQWVIRU6$(V 
3URPSWQRWLILFDWLRQRI6$(VE\WKH LQYHVWLJDWRUWR$SUHDLVHVV HQWLDOVRWKDWOHJD OREOLJDWLRQVDQG
HWKLFDOUHVSRQVLELOLWLHVWRZDUGVWK HVDIHW\RIVXEMHFWVDUHPHW 7KHVSRQVRULQYHVWLJDWRUKDVD
OHJDOUHVSRQVLELOLW\WRQRWLI\ERW KWKHORFDOUHJXODWRU\DXWKRU LW\DQGRWKHUUHJXODWRU\DJHQFLHV
DERXWWKHVDIHW\RIDSURGXFW XQGHUFOLQLFDOLQYHVWLJDWLRQ7KH VSRQVRULQYHVWLJDWRUZLOOFRPSO\
ZLWKVSHFLILFUHJXODWRU\UHTXLUH PHQWVUHODWLQJWRVDIHW\UHSRUW LQJWRWKHUHJXODWRU\


DXWKRULW\,QVWLWXWLRQDO5HYLHZ% RDUG,5%WKH)'$QRWLILFDWL RQWR$SUHDDQGVXE
LQYHVWLJDWRUV ,QYHVWLJDWRUVDIHW\UHSRUWVDU HSUHSDUHGIRUVXVSHFWHGXQH[SHFW HGVHULRXVDGYHUVH
UHDFWLRQVDFFRUGLQJWRORFDOUHJ XODWRU\UHTXLUHPHQWVDQGWKRVH SROLFLHVVHWIRUWKE\WKH)'$DQG
DUHIRUZDUGHGWRLQYHVWLJDWRUV DQG$SUHDDVQHFHVVDU\$QLQYHV WLJDWRUZKRUHFHLYHVDQ
LQYHVWLJDWRUVDIHW\UHSRUWGHVFUL ELQJDQ6$(VRURWKHUVSHFLI LFVDIHW\LQIRUPDWLRQHJ
VX[COMPANY_003]U\RUOLVWLQJRI6$(VIURP WKH+/HH0RIILWW&DQFHU&HQW HUZLOOILOHLWZLWKWKH&,%DQG
ZLOOQRWLI\WKH,(&,5%LIDSSU RSULDWHDFFRUGLQJWRORFDOUHT XLUHPHQWV

3+$50$&(87,&$/,1)250$7,21

D6WXG\7UHDWPHQWVDQG3UHSDUDWLRQ




  







2[PHONE_17268]H

)LJXUH6WUXFWXUHRI$35

E6WXG\GUXJFRPSOLDQFHDQGDFFRXQWDELOLW\
6WXG\GUXJDFFRXQWDELOLW\
7KH LQYHVWLJDWRU RU GHVLJQHH PXVW PDLQWDLQ DQ DFFXUDWH  UHFRUG RI WKH VKLSPHQW DQG


GLVSHQVLQJRIVWXG\WUHDWPHQWLQDGUXJDFFRXQWDELOLW\OHGJHU $WVWXG\FORVHRXWDQGDV
DSSURSULDWHGXULQJWKHFRXUVHRI WKHVWXG\WKHLQYHVWLJDWLRQDO SKDUPDF\ZLOOGHVWUR\DOOXVHGDQG
XQXVHGVWXG\WUHDWPHQWSDFNDJLQ JDQGGUXJODEHOVSHUWKH0&& GUXJGHVWUXFWLRQSROLF\
'LVSRVDODQGGHVWUXFWLRQ
6WXG\GUXJGHVWUXFWLRQDWWKHLQYHVWLJDWLRQDOVLWHZLOO RQO\EHSHUPLWWHGLIDXWKRUL]HGE\
$SUHDDIWHUWKHVLWHÂ¶VGUXJGHVWUXFWLRQSROLF\KDVEHHQUHYLHZH GDQGGHHPHGDFFHSWDEOHDQGLI
SHUPLWWHGE\ORFDOUHJXODWLRQV

6WXG\&DOHQGDU
$OOVFUHHQLQJHYDOXDWLRQVZLOO EHSHUIRUPHGZLWKLQZHHNVSULR UWRWKHVWDUWRI$35DQG
D]DFLWLGLQHWUHDWPHQW6XEMHFWV PXVWKDYHDERQHPDUURZELRSV\ DQGDVSLUDWHLQFOXGLQJ
F\WRJHQHWLFVSHUIRUP HGVRPHWLPHZLWKLQZHHNVSULRUWRWKHVW DUWRIWUHDWPHQW$OOWUDQVIXVLRQ
DQGSUHWUDQVIXVLRQKHPRJORELQRU SODWHOHWFRXQWP XVWEHUHFRUG HGIRUWKHZHHNVSULRUWR
LQLWLDWLRQRIVWXG\WUHDWPHQW6WU LFWDGKHUHQFHWRWKHYLVLWVF KHGXOHLVUHTXLUHG,QWKHHYHQWWKDWD
YLVLWRUWHVWFDQQRWEHVFKHGXO HGRQWKHH[DFWYLVLWGD\DZLQ GRZRIÂ“ZRUNLQJGD\VLV
DOORZDEOH7HVWVLQFOXGLQJERQHP DUURZELRSVLHVDQGDVSLUDWHV GRQHZLWKLQWKHVFUHHQLQJ
SHULRGSULRUWRVLJQLQJLQIRUPH GFRQVHQWDUHDOORZHGIRUXVHLQ WKLVVWXG\
%DVHOLQH$VVHVVPHQW ZLWKLQZHHNVRIVWDUWLQJWUHDWPHQW
0HGLFDOKLVWRU\LQFOXGLQJ
x'LVHDVHFKDUDFWHULVWLFVVXFKDV:+2)$%VXEW\SH5,366VFRUH SULRUWUHDWPHQWV
x(&2*SHUIRUPDQFHVWDWXV
x&RQFXUUHQWPHGLFDWLRQUHYLHZ
x5RXWLQHSK\VLFDOH[DPLQDWLRQ
x(.*
x%RQHPDUURZH[DPLQFOXGLQJF \WRPRUSKRORJ\F\WRJHQHWLFDVVHVVP HQWDQGIORZF\WRPHWU\
DQDO\VLV
x'RFXPHQWDWLRQRID 73JHQHPXWDWLRQE\1*6EDVHGRQFHQ WUDORUORFDOHYDOXDWLRQ
x/DERUDWRU\DVVHVVPHQWV
Å¹&%&ZLWKGLIIHUHQWLDOL QFOXGLQJSODWHOHWFRXQW
Å¹&OLQLFDOFKHPLVWULHVLQFOXGLQJ% 81FUHDWLQLQHVRGLXPSRWDVVL XPDONDOLQH SKRVSKDWDVH
$/7$67WRWDOELOLUXELQDQGDOEXPLQ


Å¹8ULQHRUVHUXPSUHJQDQF\WHVWI RUIHPDOHVRIFKLOGEHDULQJSRWHQ WLDOZLOOEHSHUIRUPHGDW
6FUHHQLQJRURQILUVWGD\RIVWX G\PHGLFDWLRQSULRUWRILUVWG RVHRIVWXG\PHGLFDWLRQ
x5HFRUGDQ\EORRGDQGEORRGVXSSRUWLYH FDUHSURGXFWVIRUWKHZ HHNVSULRUWRVWDUWRIVWXG\
PHGLFDWLRQ
7UHDWPHQW3HULRG 'D\&\FOH$35D QGD]DFLWLGLQHZLOOEHDGPLQLVWH UHG
RYHUDGD\WUHDWPHQWF\FOH3D WLHQWVZLOOKDYHPHGLFDOKLVW RU\SK\VLFDOH[DP
SHUIRUPDQFHVWDWXVHYHU\ZHHN V6XEMHFWVZLOOKDYHD&%&ZLWK GLIIHUHQWLDOLQFOXGLQJ
SODWHOHWFRXQWDQGDFRPSOHWHP HWDEROLFSURILOH &03SHUIRUPH G$%0DVSLUDWHDQG
ELRSV\ZLWKF\WRJHQHWLFDQDO\VLV ZLOOEHSHUIRUPHGDIWHUF\FOH DQG&'DQG
&'$Q1*6P\HORLGSDQHOZ LOOEHSHUIRUPHGRQ3%SULRUWRF \FOHDQGDIWHUF\FOH
DQG&'DQG&',I 73PXWDWLRQLVRQO\SUHVHQWRQ%0DQDO\VLVDW
VFUHHQLQJVHULDO1*6P\HORL GSDQHOFDQEHSHUIRUPHGRQERQHPD UURZ7KHVHDQDO\VHV
ZLOOEHXVHGWRDVVHVV SDWKRORJLFUHVSRQVHF\WRJHQHWLFUHVSRQV HPROHFXODUUHVSRQVHDQG
GLVHDVHSURJUHVVLRQ
(QGRI7UHDWPHQW 6XEMHFWVZLOOFRPSOHWHDUHVSRQVHDVVHVVPHQWZLWKLQZHHNVD IWHU
WKHLUODVWGRVHRI$35DQGD ]DFLWLGLQH6XEMHFWVGLVFRQWLQX LQJVWXG\HDUO\VKRXOG
FRPSOHWHWKHLUHQGRI WUHDWPHQWYLVLWZLWKLQZHHNVDIWHUWKHL UODVWGRVHRILQYHVWLJDWLRQDO
SURGXFW3K\VLFDOH[DPYLWDOVL JQVDGYHUVHHYHQWUHSRUWLQJ &%&&03DQG%0DVSLUDWH
DQGELRSV\ZLWKF\WRJHQHWLFDQD O\VLVZLOOEHSHUIRUPHG,IHQG RIWUHDWPHQWWHVWVDUH
GHFOLQHGRUQRWIHDVLEOH QRWFRQVLGHUHGGHYLDWLRQ

&RQWLQXDWLRQ3KDVH $IWHUFRPSOHWLQJF\FOHVRIWKHUDS\VXEMHFWVUHVSRQGLQJRU ZKRKDYH
VWDEOHGLVHDVHPD\FRQWLQXH$ 35DQGD]DFLWLG LQH%RQHPDUUR ZELRSV\DQGDVSLUDWHZLOOEH
UHSHDWHGDIWHUHYHU\F\FOHV $Q1*6P\HORLGSDQHOVKRXOGEHS HUIRUPHGRQ3%HYHU\F\FOHV
$&%&DQG&03ZLOOEHREW DLQHGHYHU\ZHHNV
(QGRIWUHDWPHQWDVVHVVPHQW LQFOXGHVEHVWUHVSRQVHDFKLH YHGGDWHRIILUVWUHVSRQVH
GDWHRIORVVRIUHVSRQVHU HDVRQIRUGLVFRQWLQXDWLRQ
2IIWUHDWPHQWIROORZXS LQFOXGHYLWDOVWDWXVGDWHRIG HDWKODVWFRQWDFWWUDQVIRUPDW LRQWR$0/
DQGWKHGDWHRIWUDQVIRUPD WLRQWR$0/LIDSSOLFDEOH

 
 
 53 Study Calendar  
Evaluation* Baseline/  
Screening  
* Lead -in phase *** Cycle 1  Cycle 2 and Subsequent 
Cycles  Every 3 
Cycles  End of  
Treatment  
**** 
Day 
-14 Day 
-13 Day 
-12 Day-
11 Day 
-10 Day 
-7 Day 
1 Day 
2 Day 
3 Day 
4a Day 
8 Day 
15 Day 
22 Prior to/  
Day 1b Days  
1-4a Day 
8 Day 
15 Day 
22   
Informed consent  X                     
Baseline medical history c X                     
Physical exam d X X      X       X      X 
Height  X                     
Weight  X X      X       X      X 
Vital Signsd X X X X X   X X X X    X X     X 
ECOG PS  X X      X       X      X 
APR -246  X X X X   X X X X     X      
Azacitidinea           X     X      
Bone marrow Biopsy and 
Aspi[INVESTIGATOR_1516] ** X     X
**              X X 
Flow Cytometry and 
Cytogenetics  X                   X X 
NGS Myeloid Panele X                   X X 
Correlative Studiesf X     X
**              X  
Response  
Assessment                     X X 
Hematology g X X     X X    X X X X  X X X  X 
Blood chemistry h X X     X X    X X X X  X X X  X 
Pregnancy test i X                     
EKGj  X    X   X   X    X       
Transfusion Log  X  <------ ------ ------------- From 8 weeks prior to randomization throughout end of treatment date  --------> 
<------------ ------- -------- Starting C1D -14 (post 1st dose) through [ADDRESS_1148275] end of tr eatment --------- >  X 
Adverse events    X 
APR -246 will be administered as monotherapy in the lead -in phase IV over 4 days (days -14 to -10) during the Phase 1b portion only*** .  
For combination therapy, APR-246 is administered IV on days 1- 4 of each 28 day cycle.  
a:   Azacitidine is administered SC or IV over 7 days starting day 4 (7 consecutive days, 4 -10; or 2+5 (i.e., days 4 -5 and 8-12))  
b:   Day 1 evaluations for subsequent cycles are to be done within 7 days prior to next cycle drug administration. 
c:   Full medical history will be obtained by [CONTACT_827622]/MD at baseline for safety and eligibility purposes, though only baseline medical history items will be 
recorded  on CRFs â€“ this will include any issues/items from 4 weeks prior to screening date.  
d:   Physical exam and vital signs (including blood pressure, heart rate, respi[INVESTIGATOR_149939]) will be completed for safety purposes though not  
recorded onto CRFs and items noted will be recorded as AEs wher e appropriate.  Vitals will be collected  prior to APR -246, 2 hours into infusion and at 
end of infusion ( +/- 30 mins at all time  points). 
e:   NGS myeloid panel will evaluate  recurrent gene mutations and TP53  VAF (secondary endpoints #4-6) at study entry a nd every 3 cycles from 
peripheral blood (PB)  mononuclear cells (MNC).   If TP53  mutation is only present on BM analysis at screenin g, serial NGS myeloid panel can  
be performed on bone marrow MNC .  Samples will be sent to Genoptix as the central laboratory for mutational analysis.   
f:   Correlative studies (secondary endpoints #7 -8) will be performed on BM MNC during screening, day  #-10 of lead in phase and every 3 cycles. If 
 
 
 54  specimen not collected  (e.g. dry tap) , not considered deviation.   
g: Hematology in cluding hemoglobin, WBC with differential, and platelet count.  
h: Blood chemistry including sodium, potassium, BUN, glucose, ALT/AST, alkaline phosphatase, total protein, total bilirubin, albumin, creatinine, and 
calcium.  
i: Pregnancy test; for women of childbearing potential, a negative pregnancy test (urine or serum) must be documented between Screening 
and first day of treatment on study.  Must be documented prior to 1st dose of medication on study  
j:   EKG prior to initial dose of APR -246 and after infusion on day -11 of the lead in phase. EKG will be performed on day 1 and at end of infusion on day 
4 of cycle 1 and then on day 1 evaluations of subsequent cycles.  
Concurrent medications will not be captured on CRFs but will be reviewed with subjects in clinic at start of cycle visits to determine if they are reveal any 
new AEs or SAEs.  For patients with documented CR or PR at disease assessment following cycle 3, hematology and blood chemistry assessments wil l be 
required for D1 of each subsequent cycle and more frequently per the discretion of the treating physician. 
 
* All screening/baseline evaluations will be performed within [ADDRESS_1148276] visit day, a window of Â±7  
     working days is allowable.    
   
**Bone marrow aspi[INVESTIGATOR_827605] # -10 in the phase 1b component of the trial.   In the phase 2 component, bone marrow assessment   
      completed within 1  month of signing consent will be accepted to fulfill screening requirement as long as it has been completed following the las t MDS   
      treatment (excluding ESAs) and there are unstained core biopsy or clot sections available for p53 immunohistochemistry.   
***Lead -in phase will only be part of the Phase 1b portion of the study.  
 
****Continuation Phase: After completing cycle [ADDRESS_1148277] stable disease or better may continue tr eatment with APR -
246 and azacitidine on 28 day cycles.  Bone marrow biopsy and aspi[INVESTIGATOR_546688] 3 cycles. A CB C and CMP will be obtained at Day 1 
of each cycle or more often per study investigator.  
 End of Cycle 6 Evaluation and End of Treatment:  Subjects discontinuing treatment early should complete their end of treatment visit within 
approximately [ADDRESS_1148278].  Physical exam, vital signs, adverse event reporting, CBC, and blood chemistry and 
BM aspi[INVESTIGATOR_827606].  
 
Off Treatment assessment: includes bes t response, date of first response, date of loss of response, reason for discontinuation. 
 Off study CRF: vital status, date of death/last contact, transformation to AML and the date of transformation to AML if appli cable.  
 
 
 
 [ADDRESS_1148279]  
 
Definitions:  Response and progression will be assessed according to modified International Working Group 
(IWG) 2006 criteria34 (Appendix B).   
 
15. STATISTICAL CONSIDERATIONS  
 
1. Study Design  
This study will be a multi-institution, open-label, phase Ib/II clinical trial conducted in 2 parts: a Phase 1b 
part followed by a Simonâ€™s two -stage Phase [ADDRESS_1148280] pre-screening NGS on peripheral blood (PB) or bone marrow (BM) samples to determine TP53  
mutational status and therefore eligibility to participate in this study. A PB sample will be obtained prior to 
treatment for NGS by [CONTACT_827623]. The initial 
Phase 1b part will evaluate APR -[ADDRESS_1148281] 3 evaluable patients 
will be enrolled using a modified 3 + 3 design. The MTD is defined as the dose level below which DLT is manifested in â‰¥33% of the patients or at dose level 1 if DLT is manifested in <33% of the patients.  
     Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby [CONTACT_827624] -[ADDRESS_1148282]- treatment clinical response assessment will be considered eligible 
for the efficacy -evaluable population and will be summarized for all efficacy variables.  Patients who fail to 
complete one treatment cycle will also be considered efficacy -evaluable if they show clear evidence of 
clinically significant disease progression. Patients who are not efficacy -evaluable will be replaced.  A 
Simonâ€™s two -stage minimax design will be applied, as follows:  
Stage 1: Enroll a total of 24 evaluable patients at the MTD (including patients who were enrolled during the 
Phase 1 part of the study).  If less than 6 of 24 patients achieve CR, then the study will be terminated early 
with the conclusion that the regimen does not warrant further investigation.  If 6 or more patients achieve 
CR, then enrollment will be permitted to continue to Stage 2.   
Stage 2: Enroll [ADDRESS_1148283] 14 of 45 patients 
achieve CR, then there is sufficient evidence to support further study of APR -246 in combination with 
azacitidine in Phase 3. Up to 39 additional evaluable patients will be treated at the level of the MTD in the 
 
 
 56 Phase 2 portion of the trial.   
This rule has the following operating characteristics:  90% power, with alpha=0.05 under the null hypothesis 
that the proportion of patients achieving CR is â‰¤ 20% versus the alternative hypothesis that it is â‰¥ 40%.  This 
design has a probability of early termination equal to 0.66 if the true CR rate is 20%.  
 
2.  Statistical Analysis Methods  
Demographic and clinical variables for the study patients will be summarized using descriptive statistics 
(mean,  standard deviation, median, inter- quartile range, range, frequency counts and percentages). Safety and 
efficacy data will be analyzed overall as well as separately for each dose cohort when appropriate.  
 
3. Safety Analysis  
This analysis will include all subjects who have received any protocol treatment, regardless of patient 
eligibility. The number (%) of subjects with adverse events, serious adverse events, and adverse events 
leading to treatment discontinuation will be reported.  Adverse events summary will be reported by [CONTACT_827625].  Laboratory parameters will also be summarized using descriptive statistics .  
 
4. Efficacy Analysis: ITT  
This analysis will include all subjects who have received any protocol treatment, regardless of patient 
eligibility or duration of treatment. Those who have no response assessment data due to reasons such as drop 
out of the study, withdrawal consent, or lost to follow-up will be treated as non-responders for various 
response evaluations. The proportion of subjects achieving the primary endpoint will be summarized.  A 95% 
exact binomial confidence interval of the proportion will also be provided for all participants treated at the MTD. In addition, a second analysis of evaluable subjects will be performed. Evaluable subjects are defined 
as those who complete at least [ADDRESS_1148284]  on treatment bone marrow biopsy 
and aspi[INVESTIGATOR_827607].  
Analyses of the following secondary endpoints will be performed as well:  
i. Duration of response defined as the time between achieving response and progression of disease. 
ii. OS at 8 months 
iii. Proportion of subjects achieving hematological improvement (HI), partial response (PR), complete response 
(CR), and/or marrow CR (mCR) by [CONTACT_190949] 2006 criteria (see appendix B)  
iv. Proportion of subjects who obtain a response as defined by [CONTACT_57937] 2006 criteria with a baseline TP53  VAF â‰¥ 
20% versus < 20% or high versus low nuclear p53 protein expression 
 
 
 57 v. Correlation of TP53  VAF with nuclear p53 protein expression as de termined by [CONTACT_827626]. Proportion of subjects who achieve â‰¥ 50% reduction in TP53 VAF. 
vii. Progression free survival (PFS) and OS in clonal responders (â‰¥ 50% reduction in TP53  VAF) versus non-
responders 
viii. Profile expression of genes related to p53- mediated signal trans duction before and after APR-246 treatment 
ix. Profile ROS production before and after APR- 246 treatment  
x. AML transformation according to World Health Organization (WHO) criteria 
xi. OS 
xii. LFS 
xiii. Determine recurrent gene mutations in ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, 
ETV6, EZH2, GATA2, GNAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PDGFRA, 
PDGFRB, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, STAT3, 
STAT5b, TET2, TP53, U2AF1, WT1, and ZRSR2 at study entry and serially th roughout treatment to assess 
changes in somatic mutation landscape.  
 
Preliminary data on the above endpoints will prove to be very useful for further investigation of this 
protocolâ€™s treatment. Such data will be summarized appropriately in an exploratory fashion. Both point 
estimates and 95% confidence intervals will be reported, if feasible. Time -to-event endpoints such as OS and 
LFS will be summarized using the Kaplan -Meier product -limit method.  
 16. Laboratory Correlates 
Unless otherwise specified, all labor atory correlates will be performed in the laboratory of [CONTACT_827636] or at 
Genoptix medical laboratory. 
1. Mutation  analyses 
Genoptix medical laboratory ([ADDRESS_1148285], Carlsbad, CA [ZIP_CODE]) will be the central laboratory for 
this study  regarding molecular profiling . All patients will undergo baseline NGS for confirmation of TP53  
mutation, baseline TP53 VAF, and identification of additional somatic mutations. These analyses will not impact enrollment into the clinical trial. Importantly,  there will be serial evaluation following cycle 3 and 
cycle 6 where NGS will be repeated to evaluate for clonal reduction of TP53  VAF as well as changes in the 
underlying mutational architecture of these patients. These analyses will be utilized for secon dary endpoints 
#4-7. For correlative genomic studies that will be performed at Genoptix medical laboratory, 2-[ADDRESS_1148286] Vacutainer tube with EDTA (purple top) as 
anticoagulant. If TP53  mutation is only present on BM analysis at screenin g, serial NGS myeloid panel 
 
 
 [ADDRESS_1148287] . In patients who become negative for TP53 mutation by [CONTACT_077] 
(VAF sensitivity for this assay is 1%  in patients with previously identified variants ), we will perform PCR -
based barcoding or digital droplet PCR to identify rare variants in an effort to determine the depth of 
remission induced by [CONTACT_827627] -[ADDRESS_1148288]. Ling Zhang  to evaluate for p53 
protein expression as a biomarker of response, correlation with TP53  VAF, and serially over the course of 
treatment (secondary endpoints # 4-5). Three sections from each core biopsy will be obtained at baseline and 
following cycle [ADDRESS_1148289] protocol (p53 antibody, clone Bp53-11, Ventana Medical Systems, Tucson, AZ, [LOCATION_003]). Nuclear 
p53 expression will be assessed quantitatively by [CONTACT_827628] p53 positivity and semi-quantitatively with an IHC 
score of stain intensity (0, 1+, 2+, and 3+) multiplied by [CONTACT_827629]. 
Shippi[INVESTIGATOR_827608]. 
       H. Lee Moffitt Cancer Center  
       [CONTACT_827637] 
       [ADDRESS_1148290] 
       Tampa, FL [ZIP_CODE] 
       Phone: ([PHONE_17265] 
 
3. In vivo  evaluation of APR-246 
As the primary mechanis m of action of APR-246 is restoration of wild-type function of p53, we will utilize 
the lead in phase of APR -246 monotherapy to assess the activation of downstream targets of p53. An 
additional 20ml of bone marrow aspi[INVESTIGATOR_827609] -study bone 
marrow (prior to Cycle #1) and on day -10 following four days of APR- 246 as well as at disease assessments 
(following cycle 3 and cycle 6; see study calendar). Utilizing the bone marrow aspi[INVESTIGATOR_4026] , the mononuclear 
 
 
 [ADDRESS_1148291] RTÂ² Profiler PCR Array (secondary endpoint #8). As production of ROS leading to DNA 
damage is an additional mechanism of action of APR-246, we will evaluate for ROS production before and 
after APR -246 monotherapy via flow cytometry (CellROXÂ® Deep Red Reagant, Life Technologies; 
secondary endpoint #9).   
i. Shippi[INVESTIGATOR_827610], wrappi[INVESTIGATOR_827611]. Specimens must be shipped via next day delivery on the day the specimen is 
obtained. DO NOT USE DRY ICE OR WET ICE. A Fedex account number will be provided for overnight 
shippi[INVESTIGATOR_007]. Call Kathy McGraw or the List laboratory at ([PHONE_17266] on the day of expected shipment to 
confirm delivery date. Shippi[INVESTIGATOR_827612].  Saturday arrivals cannot be processed. Be sure all samples are labeled appropriately with patient identifier information and designation of bone marrow.   
 
Shippi[INVESTIGATOR_827613]: 
H. Lee Moffitt Cancer Center  
Kathy McGraw or David Sallman, [CONTACT_827638] 
SRB3/23234List/x8271 [ADDRESS_1148292] 
Tampa, FL [ZIP_CODE] 
Phone: [PHONE_17267] 
 
ii. Banking  
The residuals and/or derivatives of bone marrow and blood samples collected for the correlative studies will 
be retained in the List la boratory for possible use in approved future studies. If future use is denied or 
withdrawn by [CONTACT_102], the samples will be removed from consideration for use in any future study. 
 
17. REGULATORY AND REPORTING REQUIREMENTS  
This research will be done in compliance with the applicable State and Federal laws and regulations and in 
compliance with ICH guidelines. The study description will be posted on the www.clinicaltrials.gov
 website 
in compliance with current reg ulations. The data and safety plan will be executed in accordance with ICH 
 
 
 60 guidelines and in compliance with policy and procedures at the H. Lee Moffitt Cancer Center & Research 
Institute. The following must be observed to comply with Food and Drug Adminis tration  (FDA)  regulations 
for the conduct and monitoring of clinical investigations; they also represent sound research practice: 
 
1. Informed Consent 
The investigator is responsible for patient care and for obtaining consent by [CONTACT_102]. Written informed 
consent must be obtained prior to entry of any patient. The original consent form signed and dated by [CONTACT_827630]â€™s entry into the study must be 
maintained in the Investigatorâ€™s study files.  
 
2. Use of Specimens For Research  
The patient is free at any time in the future to decide not to provide specimens or to withdraw his/her specimens from further scientific resear ch.  Such a decision will have no impact on his/her treatment or other 
aspects of participation in this study.  
 
3. Institutional Review  
No subject is to be enrolled on this protocol until the Centerâ€™s Institution Review Board has approved it. The 
protocol for this study has been designed in accordance with the general ethical principles outlined in the 
Declaration of Helsinki. The Investigator will be responsible for preparing documents for submission to the 
relevant IRB and obtaining written approval for this study. The approval will be obtained prior to the 
initiation of the study. The ap proval for both the protocol and informed consent must specify the date of 
approval, protocol number and version, or amendment number. Any amendments to the protocol after receipt of IRB approval must be submitted by [CONTACT_423878]. The Investigator is also 
responsible for notifying the IRB of any serious deviations from the protocol, or anything else that may 
involve added risk to subjects. 
 
4. Drug Accountability 
For each drug supplied for a study, an accountability ledger containing current and accurate inventory 
records covering receipt, dispensing, and the return of study drug supplies must be maintained.  Drug 
supplies must be kept in a secure, limited access storage area under the recommended storage conditions.  
These Accountability Forms must be readily available for inspection and are open to FDA inspection at any 
time.  
 
 
 61 5. IND Safety Reporting Requirements  
 
This protocol is associated with an Investigational New Drug Application (IND) supported by [CONTACT_827631] . IND 
Safety Reports are required for any adverse experience associated (or possibly associated) with the use of 
investigational product(s) that is both serious and unexpected. To meet the IND Safety reporting 
requirements set forth in 21 CFRÂ§312.32, an FDA Form 3500A (MedWatch form) will be completed and 
provided to the Moffitt Office of Institutional Regulatory Affairs for Investigational Drugs and Devices. All 
other adverse events will be reported to the FDA as part of the annual reporting requirement of the IND. 
     The initial report will include details of the current illness and serious adverse events, and an assessment 
of the causal relationship between the event and the investigational product(s). Information not available at 
the time of the initial report (e.g ., an end date for the adverse event or laboratory values received after the 
report) will be documented on the follow-up report. A final report to document resolution of the serious adverse event is required if it is not documented in the initial report. T he Moffitt Office of Institutional 
Regulatory Affairs will provide the report to the FDA as an official submission to the IND. This will occur independently of any other use of the MedWatch form or required reporting of serious adverse events. 
Submission of the MedWatch form to any other agency, including the FDA, does not fulfill this IND Safety 
Reporting requirement. Follow-up to the safety report must also be submitted to the Office of Institutional 
Regulatory Affairs in a timely manner. Upon completion of the report, a copy of all initial and follow-up 
MedWatch forms will be scanned and emailed to the Office of Institutional Regulatory Affairs and a 
telephone call will be made to confirm receipt. For unexpected fatal or life threatening experiences associated 
with the use of the investigational product(s), the Office of Institutional Regulatory Affairs will be contact[CONTACT_827632]. Notification to the FDA will be made as soon as possible, but no later than 7 
calendar days after initial recei pt of the information.  
 
6. Hospi[INVESTIGATOR_307]/Clinic Records  
Hospi[INVESTIGATOR_827614]. They will be available for 
review by [CONTACT_186572], health care personnel involved in this study, the IRB, DHHS, and the 
FDA.  
 
7. Investigator Study Files  
The Principal Investigator [INVESTIGATOR_827615] a period of 2 years following the date 
a marketing application is approved for the drug for the indication for which it is being investigated; or if no 
 
 
 62 application is to be filed or if the application is not approved for such indication, until 2 years after the 
investigation is discontinued and FDA is notified.  
The following documents should be kept in the study files:  
â€¢ A completed, signed FDA Form 1572 (Statement of Investigator) and copi[INVESTIGATOR_827616].  
â€¢ The original protocol and all amendments  
â€¢ Final IRB approval, annual renewals and all IRB correspondence  
â€¢ Blank Case Report Forms  
â€¢ Copy of all IRB approved Informed Consent forms with applicable version date  
â€¢ Updated laboratory certification and laboratory values (covering entire time of study) 
â€¢ Copy of all patientâ€™s signed informed consent forms  
â€¢ The final completed case report form for all patients  
 
8. STUDY MONITORING  
The Protocol Review & Monitoring Committee will monitor this study. Regulatory documents and case 
report forms will be reviewed rout inely by [CONTACT_827633], 
completeness and source verification of data entry, validation of appropriate informed consent process, 
adherence to study procedures, and reporting of SAEs and protocol deviations according to MCC Monitoring 
Policies. As part of the responsibilities assumed by [CONTACT_6231], the Investigator agrees to 
maintain and have available for monitoring adequate case records (accurate source documents and CRFs) for the subjects  treated under this protocol. CRFs will only be required for patients who have received at least 
one dose of study medication. In addition, the Investigator agrees to maintain all administrative documents, e.g., IRB/IEC correspondence, investigational product and supplies shipment manifests, monitoring logs, or 
Moffitt Cancer Center/designee correspondence.  The PI [INVESTIGATOR_827617], protocol violations, and other immediate protocol issues.  The study coordinator will collect information of subjects  enrolled at Moffitt and other institutions through the use of electronic or paper AE 
forms, CRF forms, End of Study forms, and Informed Consent forms.  
 
Internal Monitoring 
Data will be captured in Oncore, Moffittâ€™s Clinical Trials Database. The Case Report Forms will be reviewed 
by [CONTACT_38061]â€™s Internal Monitors, periodically, throughout the conduct of the trial. The monitoring will include 
source data verification, utilizing research subjectsâ€™ medical records . 
 
 
 [ADDRESS_1148293] copi[INVESTIGATOR_827618].  
 Data & Safety Monitoring Plan 
Identification of oversight responsibility :  
The PI [INVESTIGATOR_827619].  
The MCC Protocol Monitoring Committee (PMC): 
The PMC meets monthly and reviews accrual, patterns and frequencies of all adverse events, protocol 
violations and when applicable, internal audit results.  
Description of internal (PI) safety review and monitoring process:  
Responsible for identifying and reviewing adverse events biweekly:  
Principal Investigator  
[INVESTIGATOR_546700] :  
Adverse events by [CONTACT_479] (Gr. 3 or above using CTCAE v4.03) and attribution (expected or unexpected)  
Relationship to study drug/intervention  
Application of dose finding escalation/de- escalation rules  
Application of study designed stoppi[INVESTIGATOR_007]/decision rules  Whether the study accrual pattern warrants continuation/action  
Protocol violations  
AEs will be reported along with all other data in the Oncore database. The PI [INVESTIGATOR_827620] (CRO). The CRO will report all SAEs to Aprea, and all 
reportable SAEs to the IRB.   AE information will be entered into the CRO database. AE information will be 
managed by [CONTACT_827634].  
  
 
 
 
 
 
 64  
  
 
 
 
 
18. REFERENCES  
1. Greenberg, P.L. , et al. Myelodysplastic syndromes. Journal of the National Comprehensive Cancer 
Network : JNCCN 11, 838-874 (2013). 
2. Cazzola, M., Della Porta, M.G. & Malcovati, L. The genetic basis of myelodysplasia and its clinical 
relevance. Blood 122, 4021-4034 (2013). 
3. Greenberg, P.L. , et al. Revised International Prognos tic Scoring System (IPSS -R) for myelodysplastic 
syndromes. Blood (2012). 
4. Greenberg, P. , et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. 
Blood 89, 2079-2088 (1997). 
5. Kantarjian, H. , et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events 
not considered in the original International Prognostic Scoring System. Cancer  113, 1351-1361 (2008). 
6. Margulies, M. , et al. Genome sequencing in microfabricated high -density pi[INVESTIGATOR_827621]. Nature  437, 
376-380 (2005). 
7. Malcovati, L. , et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: 
recommendations from the European LeukemiaNet. Blood 122, 2943-2964 (2013). 
8. Papaemmanuil, E. , et al. Clinical and biological implications of driver mutations in myelodysplastic 
syndromes. Blood 122, 3616-3627; quiz 3699 (2013). 
9. Bejar, R. , et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England 
journal of medicine  364, 2496-2506 (2011). 
10. Lis t, A., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New 
England journal of medicine  355, 1456-1465 (2006). 
11. Kulasekararaj, A.G. , et al.  TP53 mutations in myelodysplastic syndrome are strongly correlated with 
aberrations of chromosome 5, and correlate with adverse prognosis. British journal of haematology  160, 
660-672 (2013). 
12. Bally, C. , et al. P-006 Prognostic value of TP53 gene mutations in higher- risk MDS treated with 
azacitidine (AZA). Leukemia Research  37, S25. 
13. Mallo, M., et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of 
cytogenetics and mutations. British journal of haematology  162, 74-86 (2013). 
14. Jadersten, M. , et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease 
progression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology  
29, 1971-1979 (2011). 
15. Fenaux, P. , et al. Efficacy of azacitidine compared with that of conventional care regimens in the 
treatment of higher -risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet 
Oncol  10, 223-232 (2009). 
16. Bally, C. , et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute 
myeloid leukemia treated with azacitidine. Leukemia research  38, 751-755 (2014). 
17. Bejar, R. , et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic 
syndrome patients. Blood 124, 2705-2712 (2014). 
 
 
 [ADDRESS_1148294] poor outcome in patients with myelodysplastic syndrome after 
hematopoietic stem-cell transplantation. Journal of clinical oncology : official journal of the American 
Societ y of Clinical Oncology  32, 2691-2698 (2014). 
19. Sallman, D.A., et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in 
myelodysplastic syndromes. Leukemia  30, 666-673 (2016). 
20. Desoutter, J., et al. Molecular prognostic factors in acute myeloid leukemia receiving first -line therapy 
with azacitidine. Leukemia  (2015). 
21. Bejar, R. , et al. TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct 
Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS -Molecular Prognosis Committee , (2014). 
22. Hou, H.A., et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups 
show the mutation is stable during disease evolution. Blood cancer journal  5, e331 (2015). 
23. Wiman, K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell death and 
differentiation  13, 921-926 (2006). 
24. McGraw, K.L. , et al. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and 
adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica (2016). 
25. Muller, P.A. & Vousden, K.H. Mutant p53 in cancer: new functions and therapeutic opportunities. 
Cancer cell  25, 304- 317 (2014).  
26. By[CONTACT_8570], V.J., Issaeva, N., Selivanova, G. & Wiman, K.G. Mutant p53-dependent growth suppression 
distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis  23, 2011-2018 (2002). 
27. Nahi, H. , et al. PRIMA -1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. 
British journal of haematology  132, 230-236 (2006). 
28. AB, A. INVESTIGATORâ€™S BROCHURE (IB) APR -246. (2016). 
29. Wiman, K.G. Pharmacological reactivation  of mutant p53: from protein structure to the cancer patient. 
Oncogene  29, 4245-4252 (2010). 
30. Lambert, J.M. , et al. PRIMA -1 reactivates mutant p53 by [CONTACT_827635]. Cancer 
cell 15, 376-388 (2009). 
31. Peng, X., et al. APR -246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a 
dedicated NADPH oxidase. Cell death & disease  4, e881 (2013). 
32. Mohell, N., et al. APR -246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. 
Cell d eath & disease  6, e1794 (2015). 
33. Lehmann, S., et al. Targeting p53 in vivo: a first- in-human study with p53-targeting compound APR-246 
in refractory hematologic malignancies and prostate cancer. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology  30, 3633-3639 (2012). 
34. Cheson, B.D., et al. Clinical application and proposal for modification of the International Working 
Group (IWG) response criteria in myelodysplasia. Blood 108, 419-425 (2006). 
35. Arber, D.A. , et al. The 2016 revision to the World Health Organization classification of myeloid 
neoplasms and acute leukemia. Blood 127, 2391-2405 (2016). 
 
 
  
 
 
 66  APPENDIX A  
Performance Status Criteria  
 
 
 
ECOG Performance Status Scale 
  
Karnofsky Performance Scale 
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able 
to carry on all pre- disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work). 80 Normal activity with effort; some 
signs or symptoms of disease.  
70 Cares for self, unable to carry on normal activity or to do active work. 
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  [ADDRESS_1148295] of his/her 
needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospi[INVESTIGATOR_373].  Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed 
or chair.  20 Very sick, hospi[INVESTIGATOR_374]. 
Death not imminent.  
10 Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].  
5 Dead.  0 Dead.  
      
 
 
 67 APPENDIX B  
 
RESPONSE CRITERIA FO R SUBJECTS WITH MDS AND CMML ACCORDING IWG 2 006 
CRITERIA34 
 
 
ALTERING DISEASE NAT URAL  HISTORY  
Complete remission (CR)  Bone marrow:  â‰¤ 5% myeloblasts with normal maturation of all cell lines  
Persistent dysplasia will be noted  
Peripheral blood:  
Hemoglobin â‰¥ 11 g/dL  
Platelets â‰¥ 100 x 109/L 
Neutrophils â‰¥ 1.0 x 109/L 
Blasts 0%  
Partial remission (PR)  All CR criteria if abnormal before treatment, except:  
Bone marrow blasts decreased by â‰¥ 50% over pretreatment but still > 5%  
Cellularity and morphology not relevant  
Marrow CR  Bone marrow:  â‰¤ 5% myeloblasts and decrease by â‰¥ 50% over pretrea tment  
Peripheral blood:  if HI responses, they will be noted in addition to marrow CR  
Stable disease (SD)  Failure to achieve at least PR, but no evidence of progression for >  8 weeks  
Failure  Death during treatment  
Disease progression characterized by [CONTACT_55579], increase in % of 
bone marrow blasts, or progression to a more advanced MDS FAB subtype than 
pretreatment  
Disease Progression (PD)  For subjects  with:  
Less than 5% blasts:  â‰¥ 50% increase in blas ts to > 5% blasts  
5%-10% blasts:  â‰¥ 50% increase in blasts to > 10% blasts  
10%-20% blasts:  â‰¥ 50% increase in blasts to > 20% blasts  
20%-30% blasts:  â‰¥ 50% increase in blasts to > 30% blasts  
Any of the following:  
At least 50% decrement from maximum remission/response levels in granulocytes or platelets  
Reduction in hemoglobin (Hgb) concentration by â‰¥ 2 g/dL  
- Transfusion dependence  
CYTOGENETIC RESPONSE  
Complete  Disappearance of the chromosomal abnormality without appearance of new ones  
Partial  At least 50% reduction of the chromosomal abnormality  
HEMATOLOGICAL IMPROV EMENT (HI)  
Erythroid response (HI -E) 
(Pretreatment < 11 g/dL)  Hgb increase by â‰¥ 1.5 g/dL  
Relevant reduction of units of RBC transfusions by [CONTACT_165634] 4 RBC transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks.  Only RBC transfusions given for a Hgb of â‰¤ 
9.0 g/dL pretreatment will c ount in the RBC transfusion evaluation  
Platelet response (HI -P) 
(Pretreatment < 100 x 109/L) Absolute increase of â‰¥ 30 x 109/L for subjects  starting with > 20 x 109/L 
Increase from < 20 x 109/L to > 20 x 109/L and by [CONTACT_2669] 100%  
Neutrophil response (HI -N) 
(Pretreatment < 1.0 x 109/L) At least 100% increase and an absolute increase of > 0.5 x 109/L 
 
 
 68 PROGRESSION/RELAPSE CRITERIA FOR SUBJECTS  WITH MDS/ CMML   
ALTERING DISEASE NAT URAL HISTORY  
Disease Progression (PD)  For subjects  with:  
Less than 5% blasts:  â‰¥ 50% increase in blasts to > 5% blasts  
5%-10% blasts:  â‰¥ 50% increase in blasts to > 10% blasts  
10%-20% blasts:  â‰¥ 50% increase in blasts to > 20% blasts  
20%-30% blasts:  â‰¥ 50% increase in blasts to > 30% blasts  
Any of the following:  
At least 50% decremen t from maximum remission/response levels in granulocytes 
or platelets  
Reduction in hemoglobin (Hgb) concentration by â‰¥ 2 g/dL  
                            Transfusion dependence  
Disease transformation  Transformation to AML (30% or more blasts)  
Relapse after CR or PR  At least one of the following:  
Return to pretreatment bone marrow blast %  
Decrement of â‰¥ 50% from maximum remission/response levels in granulocytes or 
platelets  
- Reduction in Hgb concentration by â‰¥ 1.5 g/dL or transfusion dependence  
HEMATO LOGICAL IMPROVEMENT  
Progression/relapse after HI  At least one of the following:  
At least 50% decrement from maximum response levels in granulocytes or platelets  
Reduction in Hgb by â‰¥ 1.5 g/dL 
- Transfusion dependence  
 
  
 
 
 69 APPENDIX C: 2016 WHO CLASSIFICATION FOR CMML AND MDS35 
WHO CMML  
 
           
#Not meeting WHO criteria for BCR- ABL1  CML, PMF, PV, or ET. No evidence of PDGFRA , PDGFRB , or FGFR1  rearrangement or PCM1 -JAK2  (should be 
specifically excluded in cases with eosinophilia) . If myelodysplasia is absent or minimal , CMML diagnosis can be made with acquired clonal cytogenetic/ molecular 
genetic abnormality  or monocytosis x [ADDRESS_1148296] equivalents include myeloblasts, 
monoblasts, an d promonocytes.  
 
WHO MDS  
 
 
 
     
 
     
 
    
 
   
Cytopenias defined as: hemoglobin < 10 g/dL; platelet count < 100 x 10
9/L; and absolute neutrophil count < 1.8 x 109/L.  
To be classified as dysplasia, >10% of any cell lineage must be dysplastic. PB monocytes must be < 1 X 109/L. â€ If SF3B1 
mutation is present. *Subclassified as MDS -RS with single or multi -lineage dysplasia (MDS -RS-SLD or MDS -RS-MLD). 
Pancytopenia with RS is classified as MDS -RS-MLD.   **Presence of Auer rods is classified as MDS -EB-2. *** Del(5q)  
alone or with 1 additional  abnormality except -7 or del(7q). ****1% peripheral blasts needs to be confirmed on 2 separate 
occasions to make a diagnosis of MDS -U. MDS -U diagnosis is also made with SLD and pancytopenia  or MDS defining 
cytogenetic  abnormality  in the absence of cytopenias.  WHO Subtype  Peripheral Blood  Bone Marrow  
#Chronic Myelomonocytic Leukemia  
*CMML -0 
**CMML -1 
                              ***CMML -2 
 *<2% blasts  
**â‰¥2% and <5% blasts  
***â‰¥5%  and <20%  blasts  
persistent  monocytosis >  1 x 109/L 
   and >10% of differential  
+/- cytopenias  
Leukocytosis frequent  * <5% blasts  
**â‰¥5% and <10% 
blasts  
***<20%  blasts  
>10% dysplasia in affected lineage  
***Auer Rods  
The absence of the Philadelphia 
chromoso me of bcr -abl 
fusion gene.  
 
WHO Category  Peripheral blood  Bone marrow  
MDS with single lineage 
dysplasia  (MDS -SLD)  Cytopenia (1 -2 lines)  
<1% blasts  
 Dysplasia (1 line)  
< 5% blasts  
RS < 15%/ <5%â€  
MDS  with ring sideroblasts  
(MDS -RS)* Cytopenia (1 -3 lines)  
< 1% blasts  
 Dysplasia (1 -3 lines)  
 < 5% blasts  
RS >15%/>5%â€   
MDS with  multi -lineage dysplasia  
(MDS -MLD)  Cytopenia (1 -3 lines)  
< 1%blasts  
 Dysplasia (2-3 lines)  
< 5% blasts  
RS < 15%/ <5%â€  
MDS  with excess blasts type I & 
II  
(MDS -EB-1 & MDS -EB-2**)  Cytopenia  (0-3 lines)  
Type I: 2 -4% blasts  
Type II: 5 -19% blasts  Dysplasia (1 -3 lines)  
Type I 5 -9% blasts  
Type II 10 -19% blasts  
MDS with isolated del(5q) *** Cytopenia (1 -2 lines)  
< 1% blasts  Dysplasia (1 -3 lines)  
< 5% blasts  
MDS unclassified  
( MDS -U)**** Cytopenia  (0-3 lines)  
1% or < 1% blasts  Dysplasia (1 -3 lines)  
< 5% blasts  